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Abstract
Purpose: Triplex-forming-oligonucleotides (TFOs) are able to bind DNA in a sequence-
specific manner and are a promising tool to manipulate genes or gene regulatory units
in a cellular environment. TFOs posses also a therapeutic potential e.g. as a carrier
molecule for Alpha- or Auger-electron-emitter (AEE) to target specific DNA sequences
in tumor cells. A method for the effective labeling of TFOs with the AEE iodine-125
(I-125) was established and the ability of I-125-labeled TFOs to induce site-specific
double-strand breaks (DSB) in DNA was investigated. Moreover analysis of the influ-
ence of I-125-labeled TFOs in transfected SCL-II cells with regard to cell survival, DNA
damage and the induction of cell cycle arrest were performed. Furthermore the ability
of I-125-labeled TFOs to alter gene expression of targeted genes was examined.
Methods: For that purpose two groups of TFOs were designed – TFOs specific for
single targets in the genes BCL2, BRCA1 and GAPDH and multi-binding TFOs with
several thousand binding sites in the whole genome. The cellular distribution and per-
sistence of TFOs was analyzed via flow cytometry and the I-125 labeling was per-
formed using a modified primer extension method. Cell survival was analyzed with
the colony forming assay. DNA DSB were determined using the 53BP1 assay and the
micronucleus assay. The analysis of cell cycle was done after 7-aminoactinomycin D
(7-AAD) cell staining by flow cytometry. Gene expression alteration of targeted genes
was tested via quantitative Real-Time PCR with RNA isolates from transfected SCL-II
cells.
Results: A persistence of intact TFOs in a cellular environment for at least 72 h could
be confirmed. For all tested I-125-labeled TFOs an increased cytotoxicity and DNA
damaging potential was detected. Moreover, the degree of cytotoxicity seemed to de-
pend on target localization as well as on target quantity. A pronounced induction of cell
cycle arrest in G2/M-phase 8 h post-transfection could also be detected. The gene-
specific binding of I-125-labeled TFOs led to a significant down-regulation of GAPDH
and an almost 2-fold up-regulation of BCL2 gene expression. The BRCA1 gene ex-
pression did not show any alteration.
Conclusions: The magnitude of an I-125-labeled TFO induced cytotoxic effect can be
influenced by the total number of targets as well as by the distinct location of a single
target. Therefore targeting many non-crucial targets can be as cytotoxic as targeting
one single, but crucial target and vice versa. Additionally, single gene targeting can
alter gene expression in a gene-specific manner.
1. Introduction
1.1. Discovery of DNA Triplex Structures
Since the end of the 19th century it has been known that cells contain nucleic acids,
discovered by Friedrich Miescher in 1869, who isolated various phosphate-rich chem-
icals from leukocyte nuclei [22] and named them nuclein. The role of DNA as the
source of genetic information was discovered not until 1944 by O. T. Avery [6] and
thereafter it took almost further ten years, when Watson and Crick discovered, in 1953,
the double-helix structure of the DNA [140]. In 1957 Felsenfeld at al. were able to show
that DNA does not exclusively appear in a double-helix structure, when they detected
a DNA structure composed of three polynucleotide strands, forming a triplex structure
in the presence of divalent cations [33]. This structure consists either of one poly-
purine strand and two polypyrimidine strands or one polypyrimidine and two polypurine
strands [108, 78]. Thereby the two complementary strands form a DNA double-helix
and the third strand is located in the major groove of the DNA double-helix, associ-
ated via non-Watson-Crick hydrogen bonds [33, 13]. The respective hydrogen bonds
are nowadays known as Hoogsteen hydrogen bonds [55]. Within the following two
decades not much effort was dedicated to DNA triplex research. Only in the late 1980s
the discoveries of several groups generated new impetus for DNA triplex related re-
search. In 1986 Le Doan et al. could show that homopyrimidine oligonucleotides are
able to form stable complexes with homopurine-homopyrimidine sites on duplex DNA in
a sequence-specific manner [72]. Moreover a novel DNA conformation, in supercoiled
plasmids, was discovered, whose major structural element was a triplex structure. This
DNA formation was named H-DNA [86, 91]. It was not until 1994 when Panyutin et al.
[96] introduced triplex-forming-oligonucleotides (TFOs) as possible carrier molecules
for radionuclides, which were able to deliver the radionuclides in a sequence-specific
manner into close proximity to the DNA and induce DNA double-strand breaks in spec-
ified genes. With that they lay the foundations for what was established in the first
decade of the 21st century as the antigene radiotherapy [100, 119, 98].
1
1. Introduction
1.2. Structure of the DNA Triple Helix
The basic unit of a triple helix structure is a construct of three bases, called a triplet.
Two of these bases form a classical Watson-Crick base pair consisting of two comple-
mentary bases connected by two (Adenine - Thymine) or three (Guanine - Cytosine)
Watson-Crick hydrogen bonds. The third base is connected to the base pair via non-
Watson-Crick hydrogen bonds, called Hoogsteen hydrogen bonds [55]. The third base
can only bind to the purine already engaged in the Watson-Crick base pair. All com-
binations of base triplets, important for the present work, are displayed in Figure 1.1
and were first investigated and described by Letai et al. in the third strand binding code
[75].
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Figure 1.1.: Base triplets consisting of Watson-Crick A-T and G-C base pairs bound to T, G and proto-
nated C in Hoogsteen conformation (upper picture) and to T, G, A and protonated C in re-
verse Hoogsteen conformation (lower picture). (Figure modified according to Copyright c©
ATDBio Ltd. 2005-2012)
Binding of the third base to the purine is possible in two different conformations. The
first conformation is conform to the structure discovered by Hoogsteen [55] and is
therefore called Hoogsteen conformation. In the second conformation the third base
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is twisted by 180◦ and is therefore called reverse Hoogsteen conformation. The bases
guanine, thymine and cytosine are able to bind in both orientations whereas adenine
can only attach to the purine base in reverse Hoogsteen conformation [75]. An oligonu-
cleotide can only form a triple helix when being located in the major groove of a double-
helix [37, 55] and when all bases of the third strand can adopt the same conformation.
The conformation of the third strand leads to a dedicated 5´- 3´orientation in relation to
the homopurine strand of the DNA target strand. If the bases in the third strand are in
Hoogsteen conformation, this corresponds to a parallel orientation of the third strand in
relation to the homopurine strand of the DNA target strand [72] (Figure 1.2). A reverse
Antiparallel Parallel 
5´ 3´ 5´ 
3´ 
3´ 
5´ 3´ 
5´ 5´ 
3´ 
5´ 
3´ 
minor 
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major 
groove 
Figure 1.2.: Model of the X-ray crystal structure of a triplex-forming-oligonucleotide (red) located in
the major groove of a DNA target strand (green) in antiparallel (left) and parallel (right)
orientation. (Figure modified according to Vlieghe et al. [136]).
Hoogsteen conformation corresponds to an antiparallel orientation of the third strand
[8] (Figure 1.2). Universally, oligonculeotides able to form a triple helix are termed as
triplex-forming-oligonucleotides (TFOs).
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1.3. Triplex-Forming-oligonucleotides
TFOs are able to bind complementary DNA sequences, by forming triple helices, in a
sequence-specific manner according to the third-strand binding code [75]. This means
that only if the bases of the TFO match the double-strand base sequence, correspond-
ing to the triplet combinations shown in Figure 1.1, the formation of a triple helix can oc-
cur. Triple helices almost exclusively form at homopurine-homopyrimidine sequences
in the DNA, with all purines located on one strand [72]. A purine sequence switching
once between the two strands does not inhibit triplex formation on principle but makes
a modification of the corresponding TFO necessary [24]. Homopurine-homopyrimidine
sequences of adequate length are so-called triple-helix target sites (TTSs). TTSs ap-
pear at a high frequency in the human genome especially in promoter regions [44, 45].
The adequate length of a target region and accordingly the length of a TFO neces-
sary for the specific recognition of a unique DNA sequence depends on the size of the
genome. In case of the human genome, consisting of ∼ 3x109 base pairs, a minimum
of approximately 17 base pairs must be recognized by the TFO for a specific binding
[15]. However, when designing a TFO it has to be taken into account that the binding
capabilities of the TFO are not determined by the base composition and the orienta-
tion only. The bond-angles, bond-lengths and the binding strength of the different base
triplets are also of importance when designing a TFO [9, 131].
1.3.1. Design of Triplex-Forming-oligonucleotides
1.3.1.1. Bond-Angles and Bond-Lengths of Base Triplets
The bond-angles and -lengths of base triplets refer to the C1-atom of the nucleotides
in the third strand, when the C1-atoms of the Watson-Crick base pair are used as
fixed points. If the angles and lengths of two triplet structures are equal the triplets
are termed as isomorphous. Shown in Figure 1.3 are the bond-angles and -lengths
of the potential triplets. When a TFO binds within the major groove of a double-strand
a minimal deformation of the TFO backbone is necessary. To fascilitate this structural
adaption the angles and lengths of the TFO triplets should be as isomorphic as possi-
ble. The lower the degree of isomorphism the more deformation of the TFO backbone
is needed to enable a triplex formation. As visible in Figure 1.3 only two triplets are
truly isomorphous. Solely T*A·T and C+*G·C1 in Hoogsteen conformation show similar
1 A Hoogsten bond is indicated by a "*" and a Watson-Crick bond by a "·".
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Watson-Crick Watson-Crick 
Figure 1.3.: Angles and lengths of base triplets. The angle refers to the C1-atom of the third strand
nucleotide in relation to the C1-atoms of the Watson-Crick base pair located at fixed posi-
tions. The bond length is the distance between the C1-atom of the purine base engaged in
the Watson-Crick base pair and the C1-atom of the third base. The C1-atoms of the third
strand base are shown in either the Hoogsteen or the reverse Hoogsteen conformation.
(Figure modified according to Thuong and Hélène [131])
bond-angles and -lengths. The combination of non-isomorphous triplets in a triple helix
leads to a stronger distortion of the DNA helix backbone in order to minimize the effect
of the non-isomorphism, leading to a reduced stability of the triple helix [131]. However,
non-isomorphous triplet combinations are nonetheless able to form triple helices with
homopurine-homopyrimidine DNA sequences. TFOs containing G and T [20], G and
A [8] or G, T and C [42] have been shown to form triple helices as well.
1.3.1.2. Bond Stability of Single Base Triplets
In thermal denaturation and affinity cleaving experiments it could be shown that the
most stable triplets are A*A·T, G*G·C and T*A·T in reverse Hoogsteen conformation.
Triplet formation could also be shown for the triplet combinations C*A·T, A*G·C and
T*C·G but with an almost 50% reduced bond stability in comparison to the strongest
triplets [9]. A special case represents cytosine when engaged as the third base in a
C*G·C triplet. Cytosine does built strong triplets but it can only form a triplet when
protonated at the N3 nitrogen. Therefore, triplex formation of cytosine containing TFOs
is rather pH dependent with a reduced stability at physiological and higher pH values
[131].
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1.3.2. Types of Triplex-Forming-oligonucleotides
The multiple characteristics of the basic TFO units, the triplets, lead to a multitude of
different TFO combinations within the performed studies. In most of the early works
TFOs were composed of thymine and cytosine [50]. Mainly because of their isomor-
phous structure facilitating the binding of the TFO in the major groove of the double-
helix. However, the reduced binding abilities of cytosine containing TFOs at physio-
logical or higher pH led to further investigations and the use of TFOs consisting of
guanines and adenines, which built also strong hydrogen bonds and were mostly pH
independent [8]. The guanine, adenine TFOs were first used in parallel orientation to
the duplex purine strand but triplex formation could not be confirmed . Only when used
in antiparallel orientation the triplex formation could be realized [8]. Furthermore Beal
et al. [8] could show that replacing adenine with thymine leads to increased triplex
stability. Finally, two basic types of TFOs evolved. The pyrimidine type TFOs bind-
ing with reverse Hoogsteen bonds in antiparallel orientation to the double-helix, and
the purine type TFOs binding with reverse Hoogsteen bonds in antiparallel orientation.
Both types show different characteristics and abilities with regard to pH dependance,
available ions or formation of secondary structures. Therefore, the TFO type of choice
depends on the desired application.
1.3.2.1. Pyrimidine Type
A TFO of the pyrimidine type consists always of T*A·T and C*G·C base triplets thus
the TFO sequence is fully determined by the sequence of the duplex. Cytosine and
thymine are the only isomorphous bases and can therefore form a regular backbone
conformation of the third strand [129]. In order to form a triplex the cytosine needs to
be protonated at the N3 nitrogen. This limits pyrimidine type TFOs to the use in acidic
conditions. Referring to the base triplet conformations both bases are able to adopt
the Hoogsteen as well as the reverse Hoogsteen conformation. However, Beal et al.
[8] reported that TFOs of the pyrimidine type can only form a triple helix in reverse
Hoogsteen conformation.
1.3.2.2. Purine Type
In contrast to the pyrimidine TFOs whose third strand sequence is completely deter-
mined by the sequence of the duplex, the situation is different for purine TFOs. A purine
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TFO can consist of the bases guanine, cytosine and thymine allowing the following
combinations: G*G·C, A*A·T and T*A·T. The triplex formation with a purine type TFO
is almost pH independent and is therefore preferred for triplex formation under phys-
iological conditions [38]. However, purine type TFOs need the presence of divalent
cations like magnesium, whereas monovalent cations like potassium inhibit the triplex
formation. The cellular concentration of magnesium is sufficient but the high concentra-
tion of potassium in turn induces an inhibitory effect on the triplex formation [109, 18].
The inhibitory effect of monovalent cations is particularly obvious in purine type TFOs
engaging guanine and adenine. Moreover these tend to form self-associated dimers
(homoduplexes), inhibiting the triplex formation [94]. This effect is less pronounced
when the adenine is replaced with thymine and the TFOs bind in reverse Hoogsteen
conformations [8]. A further cation-linked effect, appearing in both purine type TFOs,
is the formation of secondary structures such as G-quartetts. These G-Quartetts are
mainly formed by TFOs containing repetitive sequence tracks of four or more guanines
in a row [106]. Modification of the guanines were developed for the minimization of
the G-quartett appearance, e.g. replacing all or some of the guanines in the TFO with
2´-deoxy-6-thioguanosines, was clearly shown to reduce G-quartett formation [106].
Notwithstanding the fact that thymine is a pyrimidine, these TFOs are nevertheless
counted among the purine type TFOs. On the basis of their bond stability and ability to
form triplices under physiological conditions, most of the TFOs employed in the present
work are guanine, thymine TFOs binding in reverse Hoogsteen conformation.
1.4. Applications for TFOs
What makes TFOs an interesting tool for a multitude of cellular applications is their
capability of site-specific recognizing DNA sequences in the duplex DNA and to remain
at their point of action for long enough to efficiently interfere in a direct or indirect
manner with DNA related processes [16, 118]. TFOs binding to specific regions of the
DNA in a cellular environment are able to inhibit replication, modulate transcription and
induce site directed mutagenesis and recombination [16].
A way to inhibit DNA replication is the usage of a TFO targeting the region upstream
of the initiation site [47], where the TFO of action inhibits the binding of the DNA poly-
merase to the DNA double-strand. Another mode is the blockage of the progressing
replication fork with a TFO binding downstream of the initiation site, though requiring a
modification of the TFO to increase the binding strength, which is often achieved with
a psoralen induced cross-link [111, 27]. A comparable approach can be used for the
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TFO based modulation of transcription. A TFO positioned within the promotor region
of a specific gene is able to block the binding of transcription factors and thereby in-
hibiting the transcription initiation [105]. Inhibition of the transcriptional elongation can
be achieved by a TFO that binds tightly within the coding region and blocks the pro-
gression of the RNA-polymerase [144]. TFOs can also be used for the site-specific
induction of DNA damage, thereby increasing the frequency of mutation and recombi-
nation. Therefore TFOs are most often coupled to mutagenic agents, which are then
juxtaposed by the TFO to site-specific regions of the DNA. A frequently used muta-
genic agent is psoralen which is activated by UVA radiation and then intercalates with
DNA and covalently cross-links thymines on both DNA strands [130]. The psoralen in-
duced cross-link does not only lead to an increased mutation frequency [138] but also
enhances recombination and gene conversion at the targeted site [32]. The basic term
for the TFO based gene modulation is "antigene strategy", which also involves the spe-
cial field of "antigene radiotherapy" (1.5). The antigene radiotherapy is the generic term
for damaging selected genes by a high dose of radiation from radionuclides delivered
to this gene by specific DNA-binding molecules [99]. In antigene radiotherapy TFOs
are employed as carrier systems for radiochemicals. They mediate the highly precise
positioning of the carried compounds at their point of action along with a decline of
non-specific side effects [99].
1.5. Antigene Radiotherapy
The antigene radiotherapy represents an alternative therapeutic approach in radiation
based tumor therapy, compared to conventional radiotherapy. One severe disadvan-
tage of conventional radiotherapy are the pronounced side effects on non-cancerous
tissues due to dose delivery to normal cells. Thus a major task in radiotherapy is the
minimization of radio-damage to the surrounding normal tissues while maximizing the
radiation dose delivered to the tumor. For external irradiation this task is very com-
plicated to accomplish. Selected radionuclides induced directly into tumorous tissue
improve somehow the restraints of conventional therapy. A more promising approach
is the use of TFOs as a carrier system for short-range particle emitting radionuclides,
which is the basis of the antigene radiotherapy. Radiolabeled TFOs are able to tar-
get selected genes with high specificity, and thereby locate the carried radionuclide
in close proximity to the DNA [100]. The specificity of the TFO enables the targeting
of sequences exclusively appearing in cancerous cells and not in normal cells, reduc-
ing possible side-effects [98]. Moreover the closeness of the radionuclide to its target
enables the use of radionuclides with special characteristics that again reduce the side-
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effects to the surrounding tissue. These characteristics shall include that the radiation
primarily emitted has low energy and therefore a very limited range in tissue or em-
ploys particles with short track lengths in tissue such as α-particles. A consequence
of using radionuclides emitting low energy electrons is, that most of the energy will be
deposited in a very small volume around the decay site. The considered nuclide shall
have a half-life matching the pharmacokinetics of the carrier molecule in the cell. The
most promising radionuclides for this approach is the group of Auger-electron emitting
radionuclides (AEE) (1.6). Suitable AEE for the antigene radiotherapy include In-111
(67 h)2, I-123 (13.2 h) or Br-77 (57 h). For in vitro experiments the most convenient
AEE is I-125 (60 d). Within a first approach Sedelnikova et al. and Panyutin et al.
were able to induce specific DSBs in the human mdr1 gene by using a I-125-labeled
TFO transfected into purified nuclei, digitonin permeabelized cells and in intact cells
[119, 99]. However, the DNA DSB induction per decay was reduced by a factor of ∼
10, when compared to targeting isolated DNA.
1.6. Auger-Electron Emitters
1.6.1. Auger Electrons
Auger electrons were discovered by Pierre Victor Auger in 1923. He reported that
the irradiation of a cloud chamber with X-ray photons resulted in the appearance of
multiple electron tracks. He concluded that these electrons originated in correlation to
the ejection of inner shell electrons from the irradiated atoms [5].
1.6.2. The Generation of Auger Electrons
The emission of Auger electrons is correlated with inner shell electron vacancies. Pro-
cesses leading to an inner shell vacancy are electron capture3 (EC), internal conver-
sion4 (IC) or irradiation of nuclides with low energy X-ray photons (photoelectric effect5)
[29, 51]. These vacancies are rapidly filled by a transition of an higher shell electron,
which in turn creates another vacancy that is again filled by the transition of an even
2 In parentheses is the half-life in hours (h) or days (d).
3 An electron from an inner shell is captured by the nucleus, converting a proton into a neutron and a
neutrino is emitted.
4 The γ-quant released by the excited atomic nucleus interacts with an electron in one of the lower
atomic shells, causing the emission of the electron.
5 The emission of electrons from material as a result of being struck by photons.
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higher shell electron. Each transition results in the emission of either a characteristic
atomic X-ray photon or an Auger, Coster-Kronig, or super Coster-Kronig low-energy
electron [21], collectively termed as Auger electrons (Figure 1.4). Like that, one single
decay event can lead to the emission of a cascade of Auger electrons, and creates a
highly positive charged daughter atom [62].
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Figure 1.4.: Schematic presentation of the Auger effect as a result of the photoelectric effect. (Figure
modified according to http://de.wikipedia.org/wiki/Augerelektronenspektroskopie/Auger-
Effekt)
1.6.3. Characteristics of Auger Electrons
Auger electrons are low energy and short-range electrons released by EC or IC decay
processes [62]. During the decay of an Auger emitter up to about 30 Auger electrons
are emitted, depending on the isotope, with energies ranging between few eV to several
keV [63]. Most Auger electrons posses low energies of ∼ 20 - 500 eV [57]. As all
electrons, Auger electrons do not travel linearly in matter but in contorted paths and
their range in water totals, due to their low energies, between few nanometers and 0.5
µm. Therefore most of the energy is deposited in a very small volume around the decay
site. Since one decay produces multiple Auger electrons a high density of ionizations
is produced in a few nanometer sphere around the decay site [62].
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1.6.4. Radiobiological Effects of Auger Electrons
The deposition of high energies in a small volume make Auger-electron emitting ra-
dioisotopes very interesting as DNA damaging agents [70, 68], provided they are in
close proximity to their DNA target. It could be demonstrated that I-125, which is one
of the most extensively investigated Auger electron emitters (AEE), incorporated in nu-
clear DNA possesses a high DNA damaging potential, whereas the damage to the
cellular environment was found to be only minor [81]. Most of the induced damage
is displayed in the form of single-strand breaks (SSB), double-strand breaks (DSB),
base damage, DNA-protein-cross-links, and locally multiply damaged sites (LMDS)6.
The majority of these damages is accurately repaired by the cell except for DSB and
LMDS, whose repair is more difficult and frequently erroneous [63, 139, 48]. These
features are accountable for the high relative biologic effectiveness (RBE)7 of Auger
emitters. However, the observed effects are not only caused by the "high local depo-
sition of radiation energy from short-range Auger electrons (the radiation component)"
[82] but depend also on the influence of hydrogen radicals generated by radiolysis of
the surrounding water [137] and the neutralization effect of the highly positive charged
daughter atom [82]. The neutralization by charge transfer from the surrounding bases
can lead to destabilization and damage of the bases due to the so-called Coulomb
explosion [104].
1.6.5. DNA Damaging Effect of Auger Electrons
Due to the low energies and short track lengths of Auger electrons, they dissipate most
of their energy in a few nanometer sphere around the decay site [65, 62]. Therefore,
the damage induced by Auger electrons in DNA highly depends on the localization of
the Auger electron emitter (AEE) e.g. I-125 in relation to the target [81, 64]. Schmidt
and Hotz could show that one decay of I-125 incorporated in DNA as the thymidine
analog I-125-iododeoxyuridine ((I-125)IdU), leads on average to one DSB per decay
[114]. Additionally Martin and Haseltine [89] could determine that more than 70% of
the induced breaks by DNA incorporated I-125 occur in a sphere of 5 bp around the
decay site. Although DNA damage could be observed up to 7 nm of the decay site they
postulated that for the maximum efficiency of DSB induction the distance of I-125 to the
6 Def. LMDS: "Any of a wide variety of complex lesions, including base damage as well as double-
strand breaks, produced by "spurs" and "blobs" from a high-LET track." [48]
7 Def. RBE: "The RBE of some test radiation (r) compared with X-rays (250 keV) is defined by the
ratio D250/Dr, where D250 and Dr are, respectively, the doses of X-rays and the test radiation required
for equal biological effect." [48]
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DNA should not exceed 2 nm [89]. This postulation was confirmed by Kassis et al. who
showed that the DSB induction of I-125 positioned in close vicinity of the DNA (<1 nm)
by usage of the minor groove binder I-125-iodo-Hoechst 33342 led to a similar Decay-
DSB ratio of 1.08 DSB/decay as observed after DNA-incorporation of I-125 [64]. With
further increasing distance of I-125 to the DNA, using modified Hoechst derivatives,
the DSB yield decreased (0.52 - 0.10 DSB/decay) inversely proportional to increasing
distance [7]. The usage of a major groove binding TFO, which positions the I-125
further away from the DNA than Hoechst 33342, a DSB ratio of 0.46 DSB/decay was
reported [101], which is in good agreement with the observed coherence of distance
and DSB induction by Balagurumoorthy et al. [7] and Kassis et al. [64]. Additionally
the delivery via TFO allows the sequence-specific positioning of the I-125, respectively,
the targeted induction of DSB at a defined positions in the DNA, whereas (I-125)IdU
and I-125-iodo-Hoechst derivates are randomly distributed in the DNA. Adelstein at al.
[2] postulated that there are two mechanisms for DSB production by Auger emitters
in DNA, packed as chromatin. A direct effect at the immediate site of decay and one
indirect effect at many bases away from the decay site. However, the indirect effect
was significantly decreased experimentally in the presence of DMSO whereas no effect
could be observed on the direct effect. That led to the assumption that the scavenging
effect of DMSO reduced the effect of reactive oxygen species (ROS) created by the
Auger decay and the subsequent radiolysis of water [2]. Since the focus of the present
work was on the site specific damaging potential of I-125-TFOs, all experiments in cells
were performed in the presence of DMSO. Hence it can be assumed that all observed
effects are due to the postulated direct effect of AEE.
1.6.6. Cytotoxicity of Auger Electrons
One measure of radiotoxicity is the fraction of cells having lost their infinite capabil-
ity to reproduce after exposure to ionizing radiation. Consequently, cells still able to
reproduce infinitely is represented by the survival fraction. In general cell survival
data are plotted as the logarithm of the survival fraction as a function of applied radia-
tion dose. The mathematical modeling of survival curves produces individual shaped
curves characteristic for certain radiation qualities. There are two basic shapes of cell
survival curves. The exponential survival curve, which reflects cell killing by high-LET
or densely ionizing radiation and the linear quadratic shape, corresponding to low-LET
or sparsely ionizing radiation [12] (Figure 1.5).
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Figure 1.5.: Cell survival of mammalian cells after high- or low-LET irradiation. The high-LET survival
curve reflects the straight exponential cell killing model of densely ionizing radiation. The
low-LET survival curve reflects the linear-quadratic model of cell killing of sparsely ionizing
radiation.
Sparsely ionizing radiation e.g. X-rays or β-radiation produce especially at lower doses
repairable sublethal damage. The effects of this damage are reflected in the charac-
teristic shoulder of the curve in the low dose range. With increasing dose the sublethal
damage accumulates and leads to lethal damage and a more exponential decrease
of the survival fraction (single-target, two hits model [127]). In contrast, for densely
ionizing radiation it is assumed that each decay or hit of the target produces a lethal
damage and is therefore called single-target, single-hit model [127]. In consequence,
the survival fraction diminishes in an straight exponential way with increasing dose.
The damage produced by Auger electron emitter (e.g. I-125) when incorporated or
covalently bound to DNA is highly cytotoxic. Decays, sufficiently close to the relevant
target, are supposed to cause lethal hits and thereby cause an exponential reduction
of cell survival. Therefore Auger electron emitter causes high-LET like survival curves
in mammalian cells [62, 69].
1.6.7. Cell-Cycle Arrest caused by Auger Decay
The delay of the cell cycle and the arrest in a cell cycle phase after irradiation is a well
documented phenomenon and is part of a signaling network, known as the DNA dam-
age response (DDR). The main role of the DDR is to maintain genomic integrity after
DNA damage [87, 124]. The eukaryotic cell cycle consists of four distinct phases: G1-,
S-, G2 and M-phase. Traverse between the phases is regulated by Cyclins and Cyclin-
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dependent kinases (Cdks). Cyclins are proteins that are able to bind and activate Cdks,
which in turn phosphorylate further substrates that regulate cell cycle progression. Af-
ter irradiation and subsequent DNA damage, particularly DSB formation, the cell cycle
progression is interrupted in order to signal and repair damaged DNA. An interruption
is initiated by the activation of cell cycle checkpoints, which arrest normal cell cycle
progression at different cell cycle phases (Figure 1.6). These checkpoints exist at the
G1/S, G2/M boundary and in the S-phase [123, 46, 25].
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Figure 1.6.: Mammalian cell cycle checkpoint pathways. Figure modified according to
http://www.rndsystems.com/MiniReview_MR03_DNADamageResponse.aspx
The G1/S checkpoint was shown to be activated in many cell lines after irradiation with
increasing intensity as a function of both LET and dose [40]. However, the G1-phase
block does not appear in most p53 deficient tumor cell lines [67]. The transition from the
G1- to the S-phase is regulated by two complexes, CyclinD/Cdk4/6 and CyclinE/Cdk2.
Initiation of the G1/S1 checkpoint leads to the ataxia telangiectasia mutated (ATM)
mediated phosphorylation of p53. Also phosphorylated are murine double minute 2
(Mdm2) and checkpoint kinase 2 (Chk2) causing the activation of p53. p53 in turn up-
regulates the gene expression of p21 whose protein is an inhibitor of CyclinD/Cdk4/6
as well as CyclinE/Cdk2 thusly inhibiting the G1/S transition. Additionally, the phos-
phorylated Chk2 inhibits Cdc25A, which is an activation phosphatase for CyclinE/Cdk2
keeping this complex in an inactivated state. The latter pathway reacts more quickly to
DNA damage (< 1 h) than the slower (2-3 h) p53 dependent pathway [25, 61].
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In contrast to the G1/S and the G2/M checkpoints, the activation of the S-phase check-
point leads only to a delay and not to an arrest of the cell cycle [66]. Ionizing radiation
induced DNA DSBs activate the S-phase checkpoint, leading to the ATM mediated
phosphorylation of Chk2, which in turn dephosphorylates Cdc25A. The subsequent
degradation of Cdc25A prevents the activation of Cdk2 keeping the CyclinE A/Cdk2
complex in an inactive state. That results in a transient inhibition of replicon initiation
[66].
The G2/M checkpoint is activated in almost all eukaryotic cells in response to irradia-
tion. The duration of the subsequent arrest corresponds to the applied dose and rarely
to the radiation quality when applied at equitoxic doses [143, 11, 40]. The main control
mechanisms for the G2/M transition is the CyclinB1/Cdk1 complex, which has to be
activated by Cdc25C mediated dephosphorylation of Cdk1. In case of DNA damage,
ATM and ataxia telangiectasia and RAD3 related kinase (ATR) phosphorylate Chk1
and Chk2, which, in turn, phosphorylate Cdc25C. Consequently, Cdc25C is translo-
cated to the cytoplasm, preventing the activation of the CyclinB1/Cdk1 complex [1].
The CyclinB1/Cdk1 complex is further kept in an inactivated state by a second slowly
activated, p53-dependent pathway [85, 25]. The transition from late G2 cells to M-
phase is inhibited and the cells are arrested in late G2.
1.6.8. The Auger Electron Emitter I-125
The Auger Electron Emitter I-125 has a half life of 60.5 days [63]. The I-125 decay is
induced by electron capture mostly from the K-shell and can be divided into two stages
(Figure 1.7). In the first stage the nucleus decays to an excited metastable state of the
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Figure 1.7.: Decay scheme for I-125. (Data after Lederer et al. [73])
15
1. Introduction
tellurium-125 (Te-125) daughter by capture of an inner shell electron accompanied by
the emission of a neutrino. The thereby inner shell vacancy is filled by the transition of
an higher shell electron. The energy from the electron transition is transferred onto a
higher shell electron, which is then ejected as an Auger electron [5]. Alternatively the
energy can be emitted as an X-ray photon, which is then said to be a radiative tran-
sition. In the second stage, the metastable Te-125 state decays to the Te-125 ground
state either by internal conversion (93%) or by γ-emission (7%). Internal conversion
creates again an inner shell vacancy by transferring the available energy (35.4 keV) to
an inner shell electron which escapes as a conversion electron from the atom. As a
consequence of this vacancy a second Auger cascade runs off, leading to the emission
of further conversion electrons [93]. On average I-125 releases ∼ 15 Auger electrons
per decay [103] with the majority having energies of < 500 eV [56]. Shown in Table 1.1
are the electron emissions from I-125.
Table 1.1.: Auger, Coster-Kronig (CK) and Internal Conversion (IC) electrons from the decay of I-125.
Data after Adelstein et al. [2]
Transition Average Energy (MeV) Range (µm)
IC 1 K 3.65E-03 4.98E-01
IC 1 L 3.06E-02 1.86E101
IC M,N 3.41E-02 2.31E101
Auger KLL 2.24E-02 1.08E101
Auger KLX 2.64E-02 1.43E101
Auger KXY 3.02E-02 1.82E101
CK LLX 2.19E-04 1.02E-02
Auger LMM 3.05E-03 3.73E-01
Auger LMX 3.67E-03 5.04E-01
Auger LXY 4.34E-03 6.62E-01
CK MMX 1.27E-04 6.43E-03
Auger MXY 4.61E-04 2.25E-02
CK NNX 2.99E-05 1.15E-03
Auger NXY 3.24E-05 1.97E-03
CK OOX 6.00E-06 1.50E-04
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1.7. G-Quadruplex Forming Oligonucleotides as an Alternative
Carrier-System
TFOs as a carrier system for radioisotopes are very promising due to their high speci-
ficity and stability, but nevertheless TFOs are also limited to targets consisting of poly-
purine repeats. Recently, there is evidence that oligonucleotides are able to be part of
quadruplex structures in guanine rich sequences [95]. The basic unit of a quadruplex
is a structure consisting of four guanosin-5´-monophosphates arranged in a square co-
planar array. Each base is connected to its neighbours by two Hoogsteen hydrogen
bonds (Figure 1.8 a). These basic units are termed G-Quartetts. These arranged in
two or more stacks build up a so called "G-Quadruplex structure" (Figure 1.8 b) [125].
G G 
G G 
G G 
G G 
G G 
G G 
G G 
G G 
R 
R R 
R 
a) b) 
G G 
G G 
G G 
G G 
G G 
G G 
G G 
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I-125-C 
QFO 
GTTTT c) 
Figure 1.8.: Schematic representation of the G-Quartett; (a) and the structure of a G-Quadruplex con-
sisting of four G-Quartett units; (b). G-Quadruplex with one strand replaced by a I-125-
Oligonucleotide (QFO, bold); (c). (Figure modified according to Diculescu et al. [26].)
This G-Quadruplex in turn can be built of one, two or four guanine strands with each
strand building one of the G-Quadruplex corners.
We assume that one or more of the involved strands could be a TFO like oligonu-
cleotide, carrying an AEE (Figure 1.8 c), inducing damage to the subsequent G-quadruplex
structure during decay. These G-quadruplex structures appear at high frequencies in
the human genome and form at so-called quadruplex sequences. A genome wide sur-
vey by Todd et al. [133] identified 375,157 putative quadruplex sequences (PQS) in
the human genome and Huppert et al. [59] identified 14,769 PQS in the promotor re-
gion of 19,268 known human genes. The overall number of PQS and especially the
amount of PQS in promotor regions harbors a great potential of "quadruplex-forming-
oligonucleotides" (QFO) as additional carriers for radionuclides. However, we must be
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aware of the fact that a labeled QFO will not posses the sequence specificity of a TFO
due to its limitation to guanine repeats, but the number of targets by one QFO would
be considerably high and outnumber the few binding sites of a sequence-specific TFO.
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2. Aim of the Work
The major aim of the present study was to establish a TFO based carrier system, which
allows the site directed delivery of the AEE I-125 to specific DNA target sequences in
the cell. On this basis the cyto- and genotoxic potential of I-125-labeled TFOs should
be investigated in vitro.
To accomplish this task it was mandatory to establish a robust and efficient labeling
procedure of TFOs while the TFO binding capabilities should be remained unaffected.
Of equal importance was to characterize the target sequence specific binding of var-
ious TFOs, to investigate the DNA double-strand break capacity and the cell killing
properties of I-125-labeled TFOs.
The cyto- and genotoxic potential of I-125-labeled TFOs should be analyzed in respect
to the number and the quality of the targeted sequences.
Additionally, the biokinetics and intracellular distribution of TFOs should be charac-
terized with regard to time dependent localization and their overall persistence in the
cellular environment. Also the effects of I-125-labeled TFOs on gene expression of
targeted genes will be studied in order to elucidate the possibility of directed gene
expression manipulation by I-125-TFOs.
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3. Materials and Methods
3.1. Materials
3.1.1. SCL-II Cell Line
The squamous carcinoma cell line II (SCL-II) is derived from a undifferentiated squa-
mous epithelium carcinoma of a 91-year-old male patient [132]. SCL-II cells grow
adherent and confluent in cell culture flasks with unlimited proliferation capacity. They
show an epithelial growing pattern, a polygonal to round shape and their cytoplasm is
largely filled by the nucleus. The cell size is approximately 11 µm in diameter. In cell
culture with increased cell density they do not grow in strict monolayers but occasion-
ally in few stacked layers.
3.1.2. Oligonucleotides
All oligonucleotides used in this work were provided by Metabion international AG
(Martins-ried, Germany) with exception of the fluorochrome labeled TFOs (Alexa488),
which were delivered by TIB Molbiol GmbH (Berlin, Germany).
Table 3.1.: Triplex-Forming-oligonucleotides
Name Sequence (5´- 3´) Target-sequence (5´- 3´) Gene Reference
(locus)
TFO-MBS gag aga gag aga gag aga gag gag aga gag aga gag aga gag multi binding [121]
aga gag aga gag c aga gag aga gag g sites
TFO-V1 ggt ttg gtg gtt ggg tgt gtg gga aag gag gaa ggg aga gag cdkn2a this work
(21995579)
TFO-V2 ttt gtt ggg tgg tgg gtt ggt tgt gtt aag aga agg aag gga gga ggg cdkn2a this work
aag aaa (21969523)
TFO-V3 ggg ggt tgg ggt gtg gtg ggg ggg gcg gag atg ggc agg ggg cdkn2a this work
(21994442)
TFO-V6 ttg tgg gtg tgg tgg ggt tt aaa ggg gag gag agg gag aa cdk4 this work
(58148139)
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Table 3.1.: Continuation Triplex-Forming-oligonucleotides
Name Sequence (5´- 3´) Target-sequence (5´- 3´) Gene Reference
(locus)
TFO-V7 gtt gtg gtt gtg gtt ggg ggg aag gag aag gag aag cdk4 this work
(58148122)
TFO-V8 ggt gtt ggt tgg ttg ttt tgg tgg ggg gag gag gaa aag aag gaa bcl2 this work
tgg gg gga aga gg (60874077)
TFO- gtg ttt gtt ttt gtt ggg tgg tgt ggg gga gag gag gga aga aaa bcl2 this work
BCL2 ggg gc aga aag ag (60796002)
TFO-BCL2- Alexa488-gtg ttt gtt ttt gtt ggg ggg gga gag gag gga aga aaa bcl2 this work
Alexa488 tgg tgt ggg gg aga aag ag (60796002)
TFO-BCl2- Alexa594-gtg ttt gtt ttt gtt ggg ggg gga gag gag gga aga aaa bcl2 this work
Alexa594 tgg tgt ggg gg aga aag ag (60796002)
TFO- tgg gtg tgt gtt ggt gtg ttg ttc c gga aga aga gag gaa gag aga brca1 this work
BRCA1 ggg a (41203138)
TFO-V12 ggg tgg tgt ggg tgg gtt ttt ttt aaa aaa aag gga ggg aga gga chk2 this work
ggg (29133020)
TFO-V13 ggg ttt ttt gtg ggg gtg ttg gaa gag ggg gag aaa aaa ggg chk2 this work
(29099560)
TFO- ggg ggt ggg gtt tgt ttg ttt c g aaa gaa aga aag ggg agg ggg gapdh this work
GAPDH (6643235)
TFO-QRT aaa aac ccc cct ttt tgg ggg ctc unknown multi binding this work
sites
For the Primer-Extension Method (3.2.8) special precursor stages (preTFOs) of the
TFOs shown in Table 3.1 and biotinylated template oligonucleotides were used. The
preTFOs and oligonculeotides are displayed in Table 3.2.
Table 3.2.: Biotinylated Oligonucleotide Templates and preTFOs used for the Primer Extension Method
Name Sequence preTFO (5´- 3´) Sequence Template (5´- 3´)
preTFO- gag aga gag aga gag aga gag aga gag aaa gct ctc tct ctc tct ctc tct ctc tct ctc
MBS aga gag tct c-Biotin
preTFO- gtg ttt gtt ttt gtt ggg tgg tgt ggg g gcc cca cac cac cca aca aaa aca aac act ctt
BCL2 ctt-Biotin
preTFO- tgg gtg tgt gtt ggt gtg ttg tt gga aca aca cac caa cac aca ccc att ctt ct-Biotin
BRCA1
preTFO- ggg ggt ggg gtt tgt ttg ttt ctc gaa aca aac aaa ccc cac ccc ctt ctt-Biotin
GAPDH
preTFO-QRT aaa aac ccc cct ttt tgg ggg ct ctg agc ccc caa aaa ggg ggt ttt ttt c-Biotin
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Table 3.3.: Primer Sequences for amplification of target DNA fragments
Name Sequence (5´- 3´) Binding TFO Fragment Size Reference
BCL2 212 fwd. agc tcc cac cag ggc caa act
TFO-BCL2 212 bp
this work
BCL2 212 rev. ttc tga agg tgc cca ggc tgc this work
BCL2 1695 fwd. aca gga acc ctc cct ctg tt
TFO-BCL2 1695 bp
this work
BCL2 1695 rev. ccc ttg act gac caa atg ct this work
GAPDH 1695 fwd. tcc cac cgt gtg ccc aag
TFO-GAPDH 1695 bp
this work
GAPDH 1695 rev. ctc ctg ttt ctg ggg ac this work
GAPDH 1202 fwd. tct gcc ctc cta cca gaa ga
TFO-GAPDH 1202 bp
this work
GAPDH 1202 rev. aag aag atg cgg ctg act gt this work
Table 3.4.: Primer Sequences for amplification of Southern-Blot probes
Name Sequence (5´- 3´) Binding TFO Fragment Size Reference
GAPDH F1 fwd. cat gga aag cga atc tct gtt t
TFO-GAPDH 400 bp
this work
GAPDH F1 rev. gcc tat ctg ggc cac aag t this work
GAPDH F2 fwd. ggc cat gat tca gaa acc ac
TFO-GAPDH 595 bp
this work
GAPDH F2 rev. tca aga cca gcc tgg aaa gt this work
Table 3.5.: Primer Sequences for qRT-PCR
Name Sequence (5´- 3´) Gene Fragment Size Reference
ACTA fwd. gca aat gct tct aga cac act cca c
ACTIN 126 bp
this work
ACTA rev. cag caa cgg aag ttg tta caa aga a this work
BCL2 fwd. act cct gat tca ttg gga agt ttc a
BCL2 121 bp
this work
BCL2 rev. gca tga tcc tct gtc aag ttt cct t this work
BRCA1 fwd. gat tgg ttc ttc caa aca aat gag g
BRCA1 137 bp
this work
BRCA1 rev. gaa tcc atg ctt tgc tct tct tga t this work
GAPDH fwd. gac cac ttt gtc aag ctc att tcc t
GAPDH 134 bp
K. Knops
GAPDH rev. tct ctc ttc ctc ttg tgc tct tgc t K. Knops
3.1.3. Culture Media
Table 3.6.: Culture Media
Medium Company
Dulbecco´s modified Eagle medium: Nutrient
Mixture F-12 (DMEM: F12) with L-Glutamin, 15
mM Hepes, 1.2 g/l NaCO3
PAN
TM
Biotech GmbH, Aidenbach, Germany
L-15 Leibowitz´s medium Invitrogen, Darmstadt, Germany
Minimum essential medium Eagle (MEM) PAA Laboratories GmbH, Cölbe, Germany
with L-Glutamine
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3.1.4. Antibodies and Enzymes
Table 3.7.: Antibodies and Enzymes
Substance Company
53BP1 (H-300): sc-22760 Santa Cruz Biotechnology, Inc., Heidelberg, Germany
goat anti-rabbit IgG-TR: sc-2780 Santa Cruz Biotechnology, Inc., Heidelberg, Germany
Klenow Fragment (-Exo) Fermentas, St. Leon-Rot, Germany
Taq DNA Polymerase Fermentas, St. Leon-Rot, Germany
3.1.5. Buffer and Solutions
If not otherwise indicated all Buffer and Solutions in Table 3.8 are solved in deionized
water.
Table 3.8.: Buffer and Solutions
Buffer/ Solution Composition
Denaturation-Solution 1.5 M NaCl, 0.5 M NaOH
Developing-Solution 300 mM Na2CO3, 0.05% Formaldehyde (37%)
Freezing medium (RPE-1 cells) 10% Dimethy sulfoxide, 20% DMEM solved in FBS
Freezing medium (SCL-II cells) 10% Dimethyl sulfoxide solved in FBS
Gel-Preserving-Solution 5% Glycerol, 35% Methanol
Klenow-Buffer (x1) 500 mM Tris-HCl, pH 8.0, 50 mM MgCl2, 10 mM DTT
Loading Dye (x10) 50% Glycerol, 0.25% Bromphenolblue
Microscopy-Buffer 2.6 mM Na2HPO4 2H2O, 3 mM KH2PO4, pH 6.8
Mounting medium Sigma-Aldrich, Steinheim, Germany
Neutralization-Solution 1.5 M NaCl, 0.5 M Tris-HCl, pH 7.0
Nuclei-Extraction Buffer 320 mM Sucrose, 10 mM HEPES, 5 mM MgCl2, 1% Triton
X-100, pH 7.4
Nuclei-Wash Buffer 320 mM Sucrose, 10 mM HEPES, 5 mM MgCl2, pH 7.4
PBS-Buffer 17 mM NaH2PO4, 27 mM BaCl, 70 mM Na2HPO4
SSC-Transfer Buffer (x20) 3 M NaCl, 0.3 M Na3C6H5O7, pH 7.0
Stop-Solution 3% Acetic acid (glacial)
TAE-Buffer 40 mM Tris-Base, pH 8.0, 20 mM acetic acid, 1 mM EDTA
TBE-Buffer 89 mM Tris-Base, pH 8.0, 89 mM boric acid, 2 mM EDTA
TBP-Buffer 0.2% Triton X-100, 1% bovine serum albumine solved in PBS
TEN100 Binding Buffer 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 100 mM NaCl
TEN1000 Wash Buffer 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 M NaCl
TFO-Binding Buffer 10 mM MgCl2, 10 mM Tris-HCl, pH 5.8
TFO-Binding Buffer B 10 mM MgCl2, 10 mM Tris-HCl, pH 5.8, 16 µM Coralyne chlo-
ride hydrate
Washing Solution 1 10% SSC-Transfer Buffer (x20)
Washing Solution 2 10% SSC-Transfer Buffer (x20), 0.1% SDS
Washing Solution 3 0.005% SSC-Transfer Buffer (x20), 0.1% SDS
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3.1.6. Disposable Products
Table 3.9.: Disposable Products
Product Company
Casy R© Cups Schärfe System, Reutlingen, Germany
Cell culture flasks TPP Techno Plastic Products AG, Trasadingen, Switzer-
land
Centrifuge tubes 15 ml , 50 ml Sarstedt, Nümbrecht, Germany
Folded Filters (Grade 3 hw) Sartorius, Göttingen, Germany
Freezer vials VWR International, Darmstadt, Germany
Glass coverslips Menzel GmbH, Braunschweig, Germany
Glass Bottom Dishes (35 mm) MatTek corp., Ashland, USA
Microscope slides Menzel GmbH, Braunschweig, Germany
Nylon transfer membrane GE Water & Process Technology, Herentals, Belgium
Optical Adhesive Cover Applied Biosystems, Darmstadt, Germany
Pipette tips 10 µl, 100 µl, 1000 µl Eppendorf, Hamburg, Germany
Round Bottom Tubes 5 ml BD Bioscience, Heidelberg, Germany
Syringe Filter (20 µm) Millipore, Billerica, USA
Tubes 0.2 ml, 0.5 ml, 1.5 ml, 2 ml Eppendorf, Hamburg, Germany
Whatman paper Carl Roth, Karlsruhe, Germany
3.1.7. Chemical Reagents
The chemicals used in this work (Table 3.10) were of analytical grade.
Table 3.10.: Chemical Reagents
Chemical Company
Acetic acid (glacial) Carl Roth, Karlsruhe, Germany
Agarose low EEO AppliChem, Darmstadt, Germany
Albumin, from bovine serum Sigma-Aldrich, Steinheim, Germany
Ammoniumpersulfate (APS) Bio-Rad, Munich, Germany
β-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany
Blotting Grade Blocker Non-Fat Dry Milk Bio-Rad, Munich, Germany
Boric acid Carl Roth, Karlsruhe, Germany
Bromphenolblue (BPB) Sigma-Aldrich, Steinheim, Germany
Casy R©Ton Schärfe System, Reutlingen, Germany
Coralyne chloride hydrate Sigma-Aldrich, Steinheim, Germany
Cytochalasin B Thermo Fisher Scientific, Geel, Belgium
2´-Deoxycytidine hydrochloride (CdR) Fluka, Buchs, Switzerland
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany
Disodiumhydrogenphosphate, dihydrate Merck KGaG, Darmstadt, Germany
(Na2HPO4, 2H2O)
dNTP-Mix, 25 mM each Fermentas, St. Leon-Rot, Germany
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Table 3.10.: Continuation Chemical Reagents
Chemical Company
Dulbecco´s phosphate buffered saline (PBS) PAA GmbH, Paschingen, Austria
Ethanol (absolut) Merck KGaG, Darmstadt, Germany
Ethidium bromide (EtBr) Sigma-Aldrich, Steinheim, Germany
Ethylenediaminetetraacetic acid (EDTA) Merck KGaA, Darmstadt, Germany
Ethyleneglycoltetraacetic acid (EGTA) Merck KGaA, Darmstadt, Germany
Fetal Bovine Serum (FBS) Biochrome, Berlin, Germany
Fluorescein-dCTP (FITC-dCTP) Perkin-Elmer GmbH, Rodgau, Germany
5-Fluoro-2´-deoxyuridine (FUdR) Fluka, Buchs, Switzerland
Formaldehyde 37% (CH2O) Optichem GmbH, Inzlingen, Germany
GeneRuler
TM
10 bp DNA ladder Fermentas, St. Leon-Rot, Germany
GeneRuler
TM
100 bp DNA ladder Fermentas, St. Leon-Rot, Germany
GeneRuler
TM
500 bp DNA ladder Fermentas, St. Leon-Rot, Germany
Glycerol Serva, Heidelberg, Germany
Glycine Merck KGaA, Darmstadt, Germany
HEPES Merck KGaA, Darmstadt, Germany
Hoechst 33342 Sigma-Aldrich, Steinheim, Germany
Hygromycine B Invivogen, Toulouse, France
5-[I-125]Iodo-2´-deoxycytidine-5´-triphosphate
(I-125-dCTP)
Hartmann Analytic, Braunschweig, Germany
5-[I-125]Iodo-2´-deoxyuridine ((I-125)IdU) Perkin-Elmer GmbH, Rodgau, Germany
Immun-Star
TM
AP Substrate Bio-Rad, Munich. Germany
Methanol absolut Merck KGaA, Darmstadt, Germany
Nitric acid (HNO3) Merck KGaA, Darmstadt, Germany
Nuclease-Free dH2O Qiagen, Hilden, Germany
α-P-32-dATP Hartmann Analytic, Braunschweig, Germany
Potassium chloride (KCl) Merck KGaA, Darmstadt, Germany
ProLong Goldantifade reagent with DAPI Invitrogen, Darmstadt, Germany
7-aminoactinomycin D (7-AAD) BD Pharmingen
TM
, Heidelberg, Germany
Silver nitrate (AgNO3) Santa Cruz Biotechnology, Inc., Heidelberg, Ger-
many
Sodium acetate (NaAc) Merck KGaA, Darmstadt, Germany
Sodiumdihydrogenphpsphate, monohydrate Merck KGaA, Darmstadt, Germany
(NaH2PO4, H2O)
Sodium carbonate (Na2CO3) Merck KGaA, Darmstadt, Germany
Sodium chloride (NaCl) Merck KGaA, Darmstadt, Germany
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Steinheim, Germany
Sodium hydrogen carbonate (NaHCO3) Merck KGaA, Darmstadt, Germany
Sodium ortho vanadate (Na3V4O) Sigma-Aldrich, Steinheim, Germany
Streptavidin Magnetic Particles Roche Applied Science, Mannheim, Germany
Sucrose Sigma-Aldrich, Steinheim, Germany
Tetramethylethylenediamine (TEMED) Bio-Rad, Munich, Germany
Tris-Base Merck KGaA, Darmstadt, Germany
Tris-HCl Merck KGaA, Darmstadt, Germany
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Table 3.10.: Continuation Chemical Reagents
Chemical Company
Trisodium citrate (Na3C6H5O7) Merck KGaA, Darmstadt, Germany
Triton X-100 Carl Roth, Karlsruhe, Germany
Trypsin-EDTA PAA GmbH, Paschingen, Austria
3.1.8. Commercial Kits
Table 3.11.: Commercial Kits
Kit Company
Cell Line Nucleofector R© Kit V Lonza GmbH, Basel, Switzerland
DecaLabel
TM
DNA Labeling Kit Fermentas, St. Leon-Rot, Germany
DNeasy
TM
Blood & Tissue Kit Qiagen, Hilden, Germany
FITC Annexin V Apoptosis Detection Kit I BD Pharmingen
TM
, Heidelberg, Germany
Power SYBR R© Green RNA-to-CT
TM
1-Step Kit Applied Biosystems, Darmstadt, Germany
QIAquick
TM
PCR Purification Kit Qiagen, Hilden, Germany
RNA 6000 Nano Kit Agilent Technologies Deutschland GmbH,
Waldbronn, Germany
RNeasy
TM
Mini Kit Quagen, Hilden, Germany
Transcriptor High Fidelity cDNA Synthesis Kit Roche Applied Science, Mannheim, Germany
3.1.9. Laboratory Apparatus
Table 3.12.: Laboratory Apparatus
Apparatus Company
Agilent Bioanalyzer 2100 Agilent Technologies Deutschland GmbH,
Waldbronn, Germany
BD FACS Canto
TM
II BD Bioscience, Heidelberg, Germany
Casy R© Cell Counter Scärfe System, Reutlingen, Germany
Centrifuge 5415 R Eppendorf, Hamburg, Germany
Centrifuge Multifuge 1s-r Heraeus, Hanau, Germany
ChemiDoc
TM
XRS+ Bio-Rad, Munich, Germany
Concentrator 5301 Eppendorf, Hamburg, Germany
Gamma Counter 1480 Wizard
TM
3 Perkin-Elmer GmbH, Rodgau, Germany
Gel-Chamber Peqlab Biotechnologie GmbH, Erlangen,
Germany
Hamilton Syringe (10 µl, 50 µl) Hamilton Bonaduz AG, Switzerland
Hybridization Chamber Sheldon Manufacturing, Cornelius, USA
Imaging System FLA-5000 Fujifilm, Düsseldorf, Germany
Imaging Plates BAS 2325 Fujifilm, Düsseldorf, Germany
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Table 3.12.: Continuation Laboratory Apparatus
Apparatus Company
Incubator MCO-20 AIC Sanyo, Bad Nenndorf, Germany
Laser Scan Microscope Axio Observer. Z1 LSM
700
Zeiss GmbH, Göttingen, Germany
Magnetic Stirrer RCT basic IKAMAG R© IKA R© Werke GmbH & Co. KG,
Staufen, Germany
Microscope Axioplan 2 Zeiss GmbH, Göttingen, Germany
Mini-Protean
TM
II electrophoresis cell Bio-Rad, Munich, Germany
NanoDrop R© ND-1000 UV-VIS Peqlab Biotechnologie GmbH,
Erlangen, Germany
Nucleofector Device I Lonza GmbH, Basel, Switzerland
Protean
TM
II electrophoresis cell Bio-Rad, Munich, Germany
pH-Meter Orion Star Thermo Scientific, Meiningen, Germany
POWER PAC 3000 Bio-Rad, Munich, Germany
Real Time PCR System 7500 Applied Biosystems, Darmstadt, Germany
TProfessional Basic Thermocycler Gradient Biometra, Göttingen, Germany
Vivatome Axio Observer. Z1 Zeiss GmbH, Göttingen, Germany
Vortexer VWR International, Langenfeld, Germany
3.1.10. Software
Table 3.13.: Software
Software Company
FACSDiva Software BD Biosciences, Heidelberg, Germany
Metafer 4 Metacyte Software Metasystems, Altlusheim, Germany
Primerdesign http://frodo.wi.mit.edu/primer3/
Quantity One R© Version 4.2.1 Bio-Rad, Munich, Germany
Sequence Detection Software 1.3.1 Applied Biosystems, Darmstadt, Germany
TFO Target Sequence Search http://spi.mdanderson.org/tfo/about.php
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3.2. Methods
3.2.1. Cell Line Culture and Storage Conditions
SCL-II cells were grown in MEM with L-Glutamine, supplemented with 16% FBS in
a water-saturated atmosphere of 5% CO2 at 37◦C. SCL-II cells grow adherent and
therefore were passaged by removal of medium, one wash step with PBS and addition
of 1 ml trypsin/EDTA for 5 min at 37◦C. 5 ml of medium was added. Subcultivation
of cells was done three times a week in a ratio of 1:2 to 1:4 as needed. When used
for live cell imaging SCL-II cells were incubated in a microscope incubation chamber
which did not allow CO2 gassing. Therefore the cells were kept in L-15 Leibowitz´s
medium, which is commonly used in CO2 free systems. Before the cells were used for
live cell imaging they had to be subcultivated for at least two weeks in L-15 Leibowitz´s
medium for adaption.
For storage SCL-II cells were grown in T25 or T75 cell culture flasks to 70 - 80% conflu-
ency, then trypsinized by addition of 1 ml Trypsin-EDTA for 5 min and resuspended in at
least 4 ml MEM with 16% FBS. After determination of the cell number via Casy R© Cell
Counter the cell suspension was centrifuged for 5 min at 300 x g and the supernatant
discarded. The cell pellet was resuspended in freezing medium (FBS + 10% DMSO)
to a concentration of 1x106 cells/ml and aliquoted in freezer vials at 1 ml per vial. For
pre-cooling the vials were kept at -80◦C for three days and then transferred to -150◦C
for long time storage.
3.2.2. γ-Irradiation of SCL-II Cells
For the gamma irradiation, 1x106 SCL-II cells were cultivated in T25 cell culture flasks
for 24 h. Thereafter cells were gamma irradiated in a Cs-137 radiation chamber (0.7
Gy/min) with 1, 2, 3, 4, 6, 8 and 10 Gy. For the irradiation procedure cells were kept
in the culture flasks. As negative controls served unirradiated SCL-II cells, elsewise
treated as the irradiated cell samples. After irradiation cells were trypsinized by the
addition of 1 ml Trypsin-EDTA per flask, incubtated for 5 min at 37◦C and finally re-
suspended in at least 4 ml MEM supplemented with 16% FBS. After that cells were
counted on a Casy R© Cell Counter and the appropriate number was plated in 6-well
plates.
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3.2.3. Polymerase Chain Reaction
The Polymerase Chain Reaction (PCR) is a way to amplify DNA sequences between
two short flanking regions of known sequence. For the standard PCR reaction is
needed a DNA template, two oligonucleotide Primer, didesoxynucleotides (dNTPs) and
a heat stable DNA-polymerase (Taq-Polymerase) (Table 3.14). The standard PCR con-
sists of 5 steps, whereupon the steps 2 - 4 are repeated in 25 to 35 cycles:
1. initial Denaturation, 95◦C, 2 - 4 minutes. DNA template gets completely dena-
tured to single stranded DNA.
2. Denaturation, 95◦C, 30 - 60 seconds. Double-stranded DNA template and Template-
Primer hybrids are separated.
3. Annealing, 30 - 60 seconds. The annealing temperature depends on the Tm of
the used Primers and were determined using a gradient PCR reaction. In this
step the Primer hybridize with the DNA template.
4. Elongation, 72◦C. The duration of the steps depends on the length of the ampli-
fied sequence, estimating that 1 kbp (kilo base pairs) is synthesized per minute.
In this step the template DNA is amplified, starting at the Template-Primer hybrid.
5. final Elongation, 5 - 10 minutes, Temperature as in step 4 indicated. Ensures
that any remaining single-stranded DNA is fully extended.
A gradient PCR is a standard PCR reaction performed in a gradient Thermal Cyler
which allows to apply a temperature gradient, of approximately 10◦C, on the thermal
element of the cycler within the annealing step. Along this gradient several positive con-
trol samples are positioned and amplified. The efficiency of the amplification, screened
by agarose gel electrophoresis (3.2.4), is an indication for the ideal annealing temper-
ature.
Table 3.14.: Standard PCR-Mix; x, the volume depends on the DNA concentration
Reagent Volume
Taq Polymerase [5u/µl] 0.5 µl
10 x Taq Buffer (NH4)2SO4 5 µl
dNTP-Mix [2 mM] 2.5 µl
Primer-fwd. [10 µM] 2 µl
Primer-rev.[10 µM] 2 µl
MgCl2 [25 mM] 4 µl
DNA-Template x µl
dem. Aqua ad 50 µl
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3.2.4. Agarose Gel Electrophoresis
Agarose gel electrophoresis is a method to separate a mixed population of DNA frag-
ments on the basis of their mobility along an electric field through an agarose gel
matrix. Shorter fragments are able to move faster through the pores of the matrix than
larger molecules [90]. Separation of DNA fragments was performed in submerged hor-
izontal electrophoresis gel chambers filled with agarose gels of different concentrations
ranging from 1% to 1.5% depending on the DNA-fragment lengths. The running con-
ditions were set to a constant voltage of 90 V in TAE-Buffer for 60 to 90 min. For size
estimation of the separated DNA-fragments a DNA ladder was loaded on the gel as
well. After electrophoresis the agarose gels were incubated in a concentrated ethid-
ium bromide solution [10µg/ml] for 20 min on a rocking platform followed by a washing
step in deionized water for further 20 min. The ethidium bromide molecules intercalate
with the DNA and fluoresce with an orange color when exposed to ultraviolet light (λ
= 256 nm) and can be therefore used as an fluorescent tag for DNA [74]. The visual-
ization of the stained agarose gel was performed on a UV-table combined with a video
documentation dock site (ChemiDoc
TM
XRS+).
3.2.5. Electrophoretic Mobility Shift Assay
The Electrophoretic Mobility Shift Assay (EMSA) is a method for the electrophoretic
separation of DNA fragments interacting with other molecules like single stranded DNA,
RNA or proteins. In comparison to non-interacting DNA fragments of the same size
these fragments move slower in an electric field through a polyacrylamide gel matrix as
the mobility is determined by size, charge and shape. This effect is called a band shift
[41]. In the present work the EMSA was used as a verification method for the binding
of a TFO to its specific double-strand DNA target sequence. The polyacrylamide gels
were cast in a vertical gel chamber with a length of 20 cm in concentrations ranging
from 12% to 20% (Table 3.15), depending on the size of the DNA target fragments.
Table 3.15.: Non-denaturing Polyacrylamide gels. The quantities refer to a volume of 40 ml/gel.
Reagent 12% 20%
deionized water 15.6 ml 4.8 ml
MgCl2 ·6H2O 0.17 g 0.17 g
5 x TBE-Buffer 8 ml 8 ml
30% BIS/Acrylamide 16 ml 26.8 ml
10 % (w/v) APS 400 µl 400 µl
TEMED 40 µl 40 µl
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The gels were installed in the electrophoresis chamber and the central cooling core
was connected to a recirculating water bath, set to a temperature of 10◦C. The elec-
trophoresis tank was filled with TBE-Buffer and each gel slot was additionally jetted
with TBE-Buffer. Before loading the samples a pre-run of the gel at 100 V for 10 min
was done. The samples were mixed with 10 x Loading Dye and loaded in the gel slots
with a 50 µl Hamilton syringe. On both outer slots a DNA ladder (range depending on
sample size) was loaded. The running conditions were set to 150 V for 20 h at 10◦C.
After the run, the gel was removed from between the electrophoresis plates, placed in
a glass dish and rinsed with deionized water as a preparation for the silver staining pro-
cedure. All following steps were performed under slight shaking on a rocking platform.
The DNA in the gel was fixed by incubation in 10% ethanol for 10 min and then rinsed
in deionized water. Incubation in 1% nitric acid for exactly 3 min followed by two rinsing
steps in deionized water and two additional wash steps in deionized water for 5 min.
Incubation in 0.2% silver nitrate for 15 min. The gel was rinsed three times in deionized
water and additionally incubated for 2 min in deionized water. The Developing-Solution
was added and slightly shaken until a brown precipitate forms in the solution. The old
solution was decanted and replaced by fresh Developing-Solution. The incubation was
continued until the desired intensity of the band and background was reached. The
reaction was stopped by decanting the Developing-Solution and the addition of Stop-
Solution for 5 min. If a longer storage of the gel was needed, an overnight incubation
in Gel-Preserving-Solution was done and then stored in transparency film at 4◦C.
3.2.6. TFO Screening and Design
The screening for TFO target sequences in the human genome was done with the
"TFO Target Sequence Search" online tool (http://spi.mdanderson.org/tfo/about.php).
The screening settings were set according to the following criteria: - minimum length
of 15 bp, - guanine content minimum 50%, - no pyrimidine interrupts allowed and the
purine sequence located on one strand. The TFO sequences were designed in a com-
plementary manner to the target sequences consisting of guanines (binding guanine)
and thymines (binding adenine) in a reverse Hoogsteen conformation. A maximum of
two cytosines was allowed but only in terminal position of the TFO.
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3.2.7. In Vitro Triplex Formation and Binding Assay
All designed TFOs were additionally tested in vitro for their triplex forming abilities
with their DNA target sequences. For this testing short DNA fragments containing the
specific target sequence were synthesized. The fragments were 6 base pairs longer
on each side of the contained target sequence and were the exact duplicates of the
target regions in the genome. The target DNA fragment [1 pmol/µl] and the specific
TFO [10 pmol/µl] were mixed with TFO Binding Buffer B to a total volume of 24 µl in a
0.2 ml tube (Table 3.16). For each sample two controls were prepared. One containing
the DNA fragment (Negative Control) only and an other one containing the tested TFO
and a non-complementary DNA fragment (Non-sense).
Table 3.16.: Reaction-mix for Triplex Formation Assay
Reagent Volume
TFO/Non-sense Negative Control
10 x TFO Binding Buffer B 2.4 µl 2.4 µl
Target DNA fragment (1 pmol/µl) 2 µl 2 µl
TFO (10 pmol/µl) 2.4 µl -
deionized water 17.2 µl 19.6 µl
The samples were incubated at 37◦C for 20 - 24 h. After the incubation all samples
were analyzed in an EMSA (3.2.5). If the specific triplex formation of the tested TFOs
with their target sequences could be confirmed by EMSA these TFOs were utilizable
for further experiments. First step was the labeling with I-125 by the Primer Extension
Method (3.2.8).
3.2.8. Primer Extension Method
The Primer Extension Method is a procedure invented by Sanger and Coulson [112]
which allows the defined elongation of an oligonucleotide with a defined number of la-
beled deoxynucleoside triphosphates (dNTPs). In the present work a modified version
of the Primer Extension Method was used according to the proceedings of Panyutin
and Neumann [97] to label the used TFOs with I-125. In the first step biotinylated
oligonucleotide template and preTFO (sequences shown in Table 3.2) were mixed with
Klenow-Buffer in 0.2 ml tubes and annealed by incubation at 95◦C for 10 min followed
by slow cooling (1◦C/min) to room temperature.
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Table 3.17.: Annealing Mixture for Primer Extension Method
Reagent Volume
Oligonucleotide Template [10 pmol/µl] 0.5 µl
preTFO [10 pmol/µl] 0.5 µl
10 x Klenow Buffer 1 µl
deionized water 7.5 µl
The primer extension reaction was carried out in the presence of 2.5 units of exonuclease-
free Klenow fragment and 2.5 MBq I-125-dCTP in a total volume of 10 µl. After 15
min the reaction was stopped by heating to 75◦C for 10 min, followed by slow cooling
(1◦C/min) to room temperature. The duplex-DNA product was resuspended in TEN100
Binding Buffer. Before the labeled duplex-DNA could be bound to Streptavidin Mag-
netic Particles, the particles were prepared by three wash steps in TEN100 Binding
Buffer (500 µl each) and finally resuspended in 30 µl of TEN100 Binding Buffer. The
Streptavidin magnetic particles were mixed with the labeled duplex-DNA and incu-
bated for 15 min at room temperature. To keep the magnetic particles from settling,
slight shaking is recommended. The incubation was followed by two wash steps with
TEN1000 Wash Buffer and one more wash step in deionized water (150 µl each). The
magnetic particles were resuspended in 20 µl 0.15 M NaOH and incubated for 5 min
at room temperature for denaturation of the DNA-duplex. The magnetic particles were
removed with a magnet and the supernatant containing the I-125-labeled TFOs was
collected. Further 2.2 µl of 10 x TFO-Binding Buffer and 2 µl 1.25 M acetic acid were
added and mixed with a pipet. At this step the amount of incorporated I-125-dC was
determined by activity measurement using a 1480 Automatic Gamma-Counter. Before
further use or storage at -80◦C the labeled TFO have to be heated to 95◦C for 5 min
and directly chilled on ice for the denaturation of TFO dimers or secondary structures.
After the labeling reaction the I-125-labeled TFO have to be tested once again for their
triplex forming ability. This is necessary to exclude any unwanted modification of the
TFO due to the labeling reaction, that might inhibit the triplex formation. The testing
was done in accordance to the settings of the in vitro triplex formation and binding
assay described in 3.2.7, only differing in TFO and DNA target fragment amount. For
this, 18 - 20 kBq of I-125-labeled TFO were mixed, under binding conditions, with DNA
fragments containing the corresponding target sequence. The target fragments lengths
ranged between 200 to 1700 bp. The fragments were PCR amplificates from SCL-II
cell DNA isolates and added to the triplex reaction mix (3.16) in varying concentrations
(0.4 µg - 5 µg). After incubation the reaction mix was loaded on polyacrylamidgels
(concentration depending on DNA target size) and analyzed via EMSA and autoradio-
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graphy. The EMSA analysis is only possible for fragments shorter than 300 bp. For
longer fragments the triplex induced band shift is not distinct enough for visualization.
3.2.9. Calculation of I-125 Labeling Efficiency
The labeling efficiency of the primer extension method was calculated on the base of
the amount of preTFO loaded in the primer extension reaction mix (3.2.8) in relation to
the amount of I-125-labeled TFO at the end of the reaction. Thereby all preTFOs used
in the present work were labeled with a single I-125-dC per TFO. The calculations were
done according to the following formulas:
Specific Activity of I-125 = 81.4 kBq/pmol
Amount I-125-labeled TFO [pmol] =
Activity labeled TFO [kBq]
81.4 kBq
(3.1)
Labeling Efficiency [%] =
preTFO [pmol]
I-125-labeled TFO [pmol]
(3.2)
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3.2.10. Calculation of Accumulated I-125 Decays
The calculations of accumulated I-125- decays were done according to the following
formulas, created by Dr. E. Kümmerle.
λ =
ln(2)
t1/2
(3.3)
λ = decay constant
t1/2 = half life
A = A0× e(−λ×t) (3.4)
t = time in (h)
A = Remaining decays after time (t)
A0 = Initial value of decays
Aacc =
[
(t− (t−0.25))×1800× (A0× e(−λ×(t−0.25)))+ (A0× e(−λ×t))
]
+[
((t−0.25)− (t−0.5))×1800× (A0× e(−λ×(t−0.5)))+ (A0× e(−λ×(t−0.25)))
] (3.5)
Aacc = Accumulated decays after t
The initial value of decays A0 was determined at 22 - 24 h post transfection, for decays
measured per whole cell. A measurement of DNA bound I-125-TFO only was not
performed since the formed triplex structures do not remain intact throughout an DNA
isolation process. After the accumulation storage (t) at -150◦C samples were thawed
and incubated for 24 h. Decays that took place within this second incubation period
were not added to the final dose, since these decays accounted on average for less
than 9% of the total dose.
3.2.11. Amplification of Target DNA Fragments from DNA Isolates of
SCL-II Cells
DNA isolation from SCL-II cells was performed with the DNeasy
TM
Blood & Tissue Kit
according to the manufacturers guidelines. Typically the SCL-II cells were cultured as
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described in 3.2.1 and trypsinized with 1 ml Trypsin-EDTA for 5 min and then resus-
pended in 4 ml MEM. A maximum number of 5x106 cells was used for the isolation.
The elution step was done with 100µl of Buffer AE for an increased DNA concentration
as indicated by the manufacturer.
PCR Primer sets (Table 3.3) were designed for the amplification of DNA fragment, iso-
lated from SCL-II cells, containing the specific target sequence for the I-125-labeled
TFO. The fragment lengths varied from 200 bp to 1700 bp and the amplification was
carried out in a TProfessional Gradient Cycler as described in 3.2.3. After the ampli-
fication the samples were added up to 100 µl with deionized water and transferred in
a 1.5 ml tube. After addition of 10 µl NaAc [3 M] and 250 µl ethanol the solution was
mixed by vortexing and centrifuged at 15,000 x g for 25 min. The supernatant was
discarded and 400 µl of ethanol (70%) were added. After a further centrifugation at
15,000 x g for 5 min the supernatant was discarded and the DNA pellet dried at 37◦C
for 20 min. The pellet was resuspended in 20 µl of deionized water.
3.2.12. P-32-labeling of Southern-Blot Probes
The probes used for the southern-blot were PCR-amplified fragments of the up- and
downstream TFO target region. The primers used for the amplification are shown in
Table 3.4 and were amplified in a standard PCR reaction (3.2.3). After the amplifica-
tion the DNA was purified with the QIAquick
TM
PCR Purification Kit according to the
manufacturer´s guidelines and resolved in deionized water. P-32 labeling of the probes
was performed with the DecaLabel
TM
DNA Labeling Kit according to the manufacturer´s
guidelines with α-P-32-dATP.
3.2.13. Double-Strand Break Analysis via Southern Blotting
The Southern Blotting is a method for the detection of specific DNA sequences in DNA
samples with radioactive or fluorescent labeled probes. It was named and evolved by
Edwin Southern [126]. A Southern Blot can basically be divided into the following steps.
At first the desired DNA sample is restriction digested1, separated in a polyacrylamide
gel and then transferred and fixated on a nylon or cellulose membrane. In the last
step the fixed DNA fragments are stained with radioactive labeled RNA or DNA probes
1 Restriction digestion was not necessary in the given setting as the target DNA was a PCR amplificate
of the required size.
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which are specific for the fragments of interest [126]. In the present work the Southern
Blotting was used for the detection of breakage fragments resulting from the decay of
I-125-TFO bound to a DNA fragment containing its target sequence.
Approximately 100 kBq I-125-TFO (∼ 1.2 pmol) were added to ∼ 700 ng (∼ 0.6 pmol)
of the specific target DNA in TFO-Binding Buffer B to a total volume of 20 µl, equaling
in a molar ratio of 2:1 (TFO:DNA Target). The sample mixture was incubated at 37◦C
for 24 h. At this point a part of the mixture was used for verification of triplex formation
via autoradiography. The remaining mixture was stored for at least 60 days (1 half-life
of I-125) at -80◦C for decay accumulation. After the accumulation period the samples
were thawed and loaded on a 1% agarose gel and ran at 90 V for 90 min at room
temperature. The gel was ethidium bromide stained and photographed with a scale
of length aside. Then washed twice in 10 x volume Denaturation-Solution for 20 min
and twice in 10 times volume Neutralization-Solution for 20 min. After that the gel was
placed on a Nylon transfer membrane in a downward capillary blot assembly (Figure
3.1). For the the downward capillary transfer a stack of paper towels, slightly wider than
the gel, was placed in a glass dish and covered with four pieces of Whatman paper.
A fifth paper was soaked in 20 x SSC-Buffer (transfer-buffer) and put on top. Before
placing the membrane (as wide as the gel) on top it had to be equilibrated in deionized
water for 3 min. Bubbles were removed with a pipet. Then the gel and three pieces of
Whatman paper (soaked in transfer-buffer) with the same size as the gel are placed on
top. At least two large Whatman papers are soaked in transfer-buffer and placed on
top as shown in Figure 3.1 acting as a bridge between the gel and the transfer-buffer
reservoir. A glass plate on top of the stack can help reducing evaporation. Blotting was
performed for 1 h.
Figure 3.1.: Transfer pyramid setup for Southern blotting via downward capillary transfer [14].
After that the blotting apparatus was removed and the membrane was dried at room
temperature for 30 min. Cross-Linking of the membrane was done on the UV-table of
an ChemiDoc
TM
XRS+ for 2 min. Thereafter the membrane was rolled up with the top
facing in and placed in a 50 ml Falcon tube. 15 ml of CHURCH Buffer (3.2.14) were
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added followed by a prehybridisation at 65◦C for 4 h in a slow agitating hybridization
chamber. After the prehybridisation the buffer was replaced with fresh CHURCH Buffer
and the P-32-labeled probes (3.2.12). The hybridization was performed at 65◦C for 20
h in the hybridization chamber under slow agitation. Thereafter the buffer and probes
were discarded and 20 ml of prewarmed (65◦C) Washing Solution 1 was added for 10
min at 65◦C (all following washing steps were performed at 65◦C in the hybridization
chamber under slow agitation). Then Washing Solution 1 was removed and replaced
with 20 ml of Washing Solution 2 for 10 min. Washing Solution 2 was discarded and the
membrane was washed twice in Washing Solution 3 for 20 min each. The membrane
was taken out of the tube and dried at room temperature before being exposed to an
MS Imaging Plate for 20 min. Visualization was performed on a FLA-5000 Imaging
System.
3.2.14. CHURCH Buffer Preparation
The preparation of CHURCH Buffer is divided into two steps. At first the preparation of
the Sodium Phosphate Buffer consisting of two hydrogenphosphate solutions and then
in the second step the addition of the remaining ingredients for the CHURCH Buffer.
1. Preparation of Sodium Phosphate Buffer (0.5 M, pH 7.2)
Solution A:
Na2HPO4, 2H2O (1 M) 177,9 g
deionized water ad 1 l
Solution B:
NaH2PO4, H2O 137,99g
deionized water ad 1 l
The Sodium Phosphate Buffer is prepared by mixing both solution as follows:
Solution A 342 ml
Solution B 158 ml
deionized water 500 ml
2. Preparation of CHURCH Buffer
Sodium Phosphate Buffer (0.5 M, pH 7.2) 500 ml
EDTA (0.5 M) 2 ml
BSA 10 g
SDS 70 g
The BSA has to be dissolved in small amounts (per 1g) in 50 ml deionized water at
room temperature. The SDS must also be dissolve in small amounts in 400 ml of
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deionized water while stirring and heating. All ingredients were added to the Sodium
Phosphate Buffer while slow stirring at room temperature followed by filtration with a
0.2 µm pore size syringe filter.
3.2.15. Transfection Procedure
Transfection via electroporation is a method for the permeabilization of cell membranes
to insert DNA into eucaryotic cells. The basic principle is the "temporary increase of
the membrane permeability due to reversible electrical breakdown of the plasma mem-
brane upon application of external high-intensity field pulses of very short duration"
[147]. The transfection method used in the present work was the Lonza Nucleofec-
tor system which is a system that combines the electroporation principle with cell type
specific solutions. It permits the transfer of DNA or oligonucleotides directly into the
nucleus of a living cell with a high efficiency (http://www.lonza.com/). This character-
istic made it applicable for our needs. The transfection of the cell lines in the present
work was done on the Lonza Nucleofector Device I combined with the Nucleofector R©
Kit V according to the manufacturer´s guidelines.
3.2.15.1. Transfection of SCL-II Cells
SCL-II cells were grown in T25 cell culture flasks (as described in 3.2.1) to 70 - 80%
confluency, then trypsinized by addition of 1 ml Trypsin-EDTA for 5 min and finally
resuspended in at least 4 ml MEM with 16% FBS. The cells were counted on a Casy R©
Cell Counter and the required number (2x106) was transferred into a 15 ml Falcon tube
and centrifuged for 10 min at 90 x g. The supernatant was removed and the cell pellet
was resuspended in 100 µl Nucleofector Solution. The required amount of TFO was
added and the solution was transferred into the transfection cuvette (supplied with the
Nucleofector R© Kit V). The electroporation reaction was performed on the Nucleofector
Device I employing transfection program L-013. Immediately after the reaction 500 µl
pre-equilibrated MEM with 16% FBS were added and the cell solution was transferred
into a T25 cell culture flask (final volume of 10 ml media per flask) or aliquoted into a
6-well plate (final volume of 1.5 ml media per well), and incubated at 37◦C.
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3.2.16. SCL-II Cell Treatment for (I-125)ldU Incorporation
Deoxyuridine is a base analogue to deoxythymidine and is incorporated into cellular
DNA during replication. In the present work the I-125-labeled deoxyuridine (I-125)IdU
works as a carrier and enables the incorporation of I-125 into the DNA. To maximize
the (I-125)IdU incorporation cells were synchronized in G1-phase by contact inhibition
as the added (I-125)IdU is only incorporated during the replication in the following
S-phase. Moreover the cellular pyrimidine synthesis was blocked by the addition of
FUdR, to minimize the inhibitory effect of intracellular thymidine on the incorporation of
the added (I-125)IdU. As the cytosine synthesis is also affected by the FUdR blockage
CdR had to be added as a substitute
SCL-II cells were grown in T75 cell culture flasks for 5 days. A cell confluency of 100%
should be reached as a synchronization of cells due to contact inhibition was intended.
After that the cells were trypsinized by addition of 1 ml Trypsin-EDTA for 5 min and
resuspended in 20 ml MEM with 16% FBS. The cells were kept in the same culture
flask and further incubated for 3 more days. After that the cells were trypsinized resus-
pended in MEM with 16% FBS and aliquoted in T10 cell culture flasks at 1x106 per flask
and incubated for 10 h. Thereafter 100 pmol/µl FUdR, 100 pmol/µl CdR and 1 kBq/ml
(I-125)IdU were added (total volume 3 ml) and incubated for 20 h. Negative controls
were treated the same way but instead of (I-125)IdU 100 pmol/µl non-radioactive IdU
was added. After the incubation the cells were washed twice with PBS, trypsinized
and resuspended in MEM with 16% FBS. Before centrifugation at 300 x g for 5 min
the cell number was counted on a Casy R© Cell Counter. After centrifugation the cells
were resuspended in freezing medium (FBS + 10% DMSO) and stored in freezer vials.
Before storage at -150◦C for decay accumulation the specific activity of each vial was
determined on a Gamma Counter 1480 Wizard
TM
3.
3.2.17. Flow Cytometry
The flow cytometry is an application based on the analysis of cells flowing at high
speed past a beam of exciting light. Different detectors are positioned at the point
where the cells pass the light beam. The detector located in line with the beam is the
Forward Scatter (FSC) whose signals correlate with the cells volume, perpendicular to
the beam is the location of the Side Scatter (SSC) measuring the scattered light as a
degree for the cytoplasmic granularity or membrane roughness of the cells. Additional
fluorescence detectors allow the discrimination of different fluorescent stains which can
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be used for staining of whole cells or cellular structures [39]. The flow cytometer used
for the following analysis was a BD FACS Canto
TM
II equipped with two laser beams for
488 nm and 523 nm.
3.2.17.1. Cell Cycle Analysis of SCL-II Cells
In the present work the cell cycle analysis was done by flow cytometry after perme-
abilisation and 7-aminoactinomycin D (7-AAD) staining of SCL-II cells. 7-AAD is a
fluorescent DNA intercalator which enables the relative quantification of DNA in cells.
On the basis of the DNA content the different cell cycle phases can be distinguished
as the DNA content differs between the phases [71].
The aim of the cell cycle analysis in the present work was to study the influence of
I-125-labeled and unlabeled TFOs in SCL-II cells on the duration of the different cell
cylce phases. For this purpose SCL-II cells were transfected as described in 3.2.15.1
with ∼ 100 kBq of I-125-TFO or 5 pmol of unlabeled TFO and incubated in T25 cell
culture flasks for 22 h at 37◦C. After the incubation the cells were trypsinized and stored
in freezing medium (FBS + 10% DMSO) at -150◦C for decay accumulation. After the
accumulation period the cell samples were thawed and each sample was aliquoted on
several T25 cell culture flasks at 5x105 cells per flask and cultured at 37◦C. Each of the
flasks was used for one measurement time point which were set after 0 h, 8 h, 16 h,
24 h, 32 h, 40 h and 48 h. At each time point the cells were trypsinized, resuspended
in MEM, and transferred into a 15 ml falcon tube. After centrifugation (5 min, 400 x g,
RT) the cell pellet was resuspended in 1ml PBS and transferred into a 2 ml tube. After
a further centrifugation (5 min, 400 x g, RT) and one additional wash step in PBS the
sample was centrifuged (5 min, 400 x g, RT) and fixed by the addition of 300 µl PBS
and 700 µl Ethanol (100%). The 7-AAD stain was performed as follows. At first the
cells were washed twice in PBS and then resuspended in 100 µl PBS + 5 µl 7-AAD
staining solution. After staining for 25 min at RT 500 µl PBS were added and then
analyzed in a BD FACS CANTO
TM
II flow cytometer.
3.2.17.2. Biokinetic of TFOs in SCL-II Cells
In the following assay the kinetic behavior of Alexa488-labeled TFOs in SCL-II cells was
analyzed, focusing on localization, stability and retention time of the TFOs in the cells.
The Alexa488 fluorochrome shows excitation/emission maxima at 495/519 nm. SCL-II
cells were transfected with 100 pmol of Alexa488-labeled TFO-BCL2 (3.2.15.1) and
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incubated in two 6-well plates (3x105 cells/well) at 37◦C. After 1, 6, 12, 18, 24, 30, 48
and 72 h the medium in one well was discarded, the cells were washed with PBS and
subsequently trypsinized with Trypsin-EDTA and resuspended in 2 ml MEM with 16%
FBS. The cell solution was transferred in 5 ml round bottom tubes and centrifuged for 5
min at 300 x g at room temperature (all following centrifugation steps were performed
with these settings). The supernatant was discarded and the cell pellet washed twice in
PBS and finally resuspended in 500 µl PBS. After the addition of 5 µl propidium iodide
the samples were incubated for 15 min at RT. Thereafter the cells were analyzed up to a
maximum of 10,000 events in the flow cytometer. The fraction of apoptotic and necrotic
cells, respectively, was determined on basis of the measured propidium iodide signal.
Beside the analysis of whole cells also isolated cell nuclei were tested. Therefore the
cells were further processed following a nucleic isolation protocol. At first the cells
were resuspended in Nuclei-Extraction Buffer by vortexing for 10 sec and incubation
for 10 min on ice. After centrifugation the supernatant was discarded and the pellet
washed two times in 2 ml Nuclei-Wash Buffer. Prior to the flow cytometric analysis
the isolated nuclei were resuspended in 500 µl Nuclei-Wash Buffer. Sham transfected
cells were used as negative controls and were also treated as previously described.
The fluorescence measured in the negative controls displayed the background signal
and was used to set the threshold for TFO positive samples.
3.2.18. Live Cell Imaging of SCL-II Cells
Live cell imaging is a technique that allows the microscopical monitoring of cellular dy-
namics and physiological processes. The study of these processes needs live imaging
over time which in turn requires special imaging equipment that provides the neces-
sary conditions for living cells. That means a constant temperature of 37◦C, provided
by a microscopic heating chamber, and if possible a CO2 gassing. The CO2 gassing
can be omitted if the cells are kept in L-15 Leibowitz´s medium, which does not require
a controlled atmosphere. Moreover the cells have to be cultivated in cell dishes with
coverslip bottoms (glass bottom dishes). The imaging was performed on a Zeiss Vi-
vatome combined with a Axio Observer. Z1 fluorescence microscope, driven by the
AxioVision software, which allows surveilance of multiple cells throughout the whole
testing period.
In the present work live cell imaging was used to monitor the biokinetics of Alexa594-
labeled TFOs in SCL-II cells. Alexa594 shows excitation/emission maxima at 590/617
nm and was used due to its greater photo stability in comparison to Alexa488, which
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was used for flow cytometric analysis. At first SCL-II cells were grown in L-15 Lei-
bowitz´s medium2 and transfected with 100 pmol of Alexa594-labeled TFO-BCL2. Af-
ter transfection the cells were transferred into glass bottom dishes and incubated in the
microscopic heating chamber until they settled and got adherent to the glass surface.
Thereafter 20 solitary growing, adherent cells were chosen and tracked for the next 16
h at an interval of 2 h. For imaging a Plan-Apochromat 100x/1.40 Oil DIC oil immersion
objective was used combined with a Texas red T7 filter for fluorescent imaging. For
each image a DIC and a fluorescent picture was taken and finally merged. The focus
position was set so that the nucleus was clearly visible, with a Z-stack diameter of 0.5
µm. Though a focus drift due to thermal expansion could not be excluded, the focus
was manually refocused at each time point.
3.2.19. RNA Isolation from SCL-II Cells
The RNA isolation from SCL-II cells was performed with the RNeasy
TM
Mini Kit ac-
cording to the manufacturere´s guidlines. The RNA purity was determined using a
NanoDrop R© photometer whereas the values for 260/280 nm (protein contamination)
and 260/230 (organic solvent contamination) had to be in the range of 2.0 ± 0.2 to be
usable for further applications. The RNA quality was analyzed with a lab-on-a-chip sys-
tem using the RNA 6000 Nano Kit in the Bioanalyzer 2100. Determining for the RNA
quality was the RIN-Value (RNA Integrity Number) which shows the relation of 18S- to
28S ribosomal RNA (rRNA). RIN-Values range from 1 to 10 whereas 1 reflects a totally
degraded RNA and 10 completely intact RNA. For further applications only RNA with
a RIN-Value of at least 8 were used. The RNA isolates were stored for further use at
-80◦C.
3.2.20. Quantitative Real-Time PCR
The quantitative Real-Time PCR (qRT-PCR) is a method for quantification of nucleic
acids. It is based on the standard PCR reaction as described in 3.2.3 but additionally
allows the monitoring of the amplification process in real time. The basic principle is the
detection of a fluorescent DNA intercalator (EtBr, SYBR-Green) which signals intensity
increases in proportion to the progressing DNA amplification [52]. The qRT-PCR can
2 The use of Leibowitz´s medium was necessary as the provided microscopic heating chamber did not
allow CO2 gassing.
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also be used to quantify messenger RNA (mRNA) or non-coding RNA when combined
with a reverse transcriptase PCR.
In the present work the quantification of mRNA was used to determine the expres-
sion of specific genes in SCL-II cells after the transfection with gene specific binding
I-125-TFOs. The SCL-II cells were transfected as described in 3.2.15.1 with ∼ 100
kBq of I-125-TFO or the analog but unlabeled TFO [5 pmol], incubated for 20 - 23 h
at 37◦C and then stored in freezing medium at -150◦C for decay accumulation. After
the accumulation period the cells were thawed and cultured for 20 - 23 h at 37◦C in
T25 cell culture flasks. Thereafter the cells were trypsinized and an RNA isolation was
done as described in 3.2.19. The effect of three different TFOs was tested, which were
designed to bind within one of the following genes, BRCA1, BCL2 or GAPDH. As en-
dogenous control or housekeeping genes GAPDH (for BCL2 and BRCA1) and ACTIN
were used. The housekeeping gene expression was determined for each sample. Be-
fore starting the qRT-PCR, primer sets (Table 3.5) specific for the selected genes were
designed. The primer were constructed in accordance with the following characteris-
tics. A product length between 100 bp to 150 bp, annealing temperature 59◦C and the
melting temperature (Tm) within a range of 65◦C to 85◦C but ideally at 75◦C. Before
use the primer sets were tested for their specificity in a standard PCR (3.2.3) with a
template originating from a whole RNA isolate transcribed into cDNA via cDNA synthe-
sis (3.2.21). For the qRT-PCR the Power SYBR R© Green RNA-to-CT
TM
1-Step Kit was
used. Shown in Table 3.18 is the component mix for one sample of a qRT-PCR.
Table 3.18.: Component Mixture for one qRT-PCR sample
Reagent Volume
Primer fwd. [10 µM] 1 µl
Primer rev. [10 µM] 1 µl
RT-Enzyme Mix (x125) 0.16 µl
RT-PCR Mix (x2) 10 µl
RNA-Template [30 ng/µl] 1 µl
nuclease free dH2O 6.84 µl
Each I-125-TFO was tested in three biological replicates, prepared in independent
transfection reactions. Each replicate was loaded on a 96-well plate in three techni-
cal replicates that were automatically averaged by the software. In the first step of
the qRT-PCR the Master Mix (without RNA-Template) was prepared and loaded on a
cooled 96-well plate. In the second step the RNA-Template was added and the 96-
well plate was covered with an optical adhesive cover and centrifuged (1 min, 300 x g,
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4◦C). Subsequently the plate was placed in a qRT-PCR cycler and the qRT-PCR was
performed using the program shown in Table 3.19.
Table 3.19.: qRT-PCR Program
Step Temperature Time
cDNA-Synthesis 50◦C 30 min
initial Denaturation 95◦C 15 min
Denaturation 94◦C 15 sec
Hybridisation 59◦C 30 sec x40
Elongation 72◦C 40 sec
After the qRT-PCR the specificity of the amplificated product was measured using a
melting curve analysis, starting at 59◦C and increasing stepwise up to 95◦C. The eval-
uation of the results was done with the Sequence Detection Software. The software in-
tegrated the technical replicates per sample, allowed the normalization of the detected
signals on the basis of the passive reference dye ROX, and calculated the expression
of the measured sample in comparison to untreated controls (relative expression). The
basis for the calculations were as follows:
1. Normalization in relation to the endogenous control (GAPDH, ACTIN)
Ct Sample - Ct endogenous control (GAPDH, ACTIN) = ∆Ct Sample/ Calibra-
tor
2. Normalization to Calibrator (negative control)
∆Ct Sample - ∆Ct Calibrator (negative control) = ∆∆Ct
3. Substituted in the formula
2−∆∆Ct
The ∆∆Ct values were further analyzed with Microsoft Excel. That comprised the in-
tegration of the biological replicates and the calculation of the significance using the
Student´s t-test.
3.2.21. cDNA Synthesis
To test the specificity of the qRT-PCR primer (3.5) first of all a whole RNA isolate from
SCL-II cells (3.2.19) was transcribed into cDNA in a reverse transcription synthesis.
For this, the Transcriptor High Fidelity cDNA Synthesis Kit was used, which contained
all necessary reaction components. At first the Template-Primer Mix (Table 3.20) was
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prepared in a 0.2 ml tube, heated for 10 min to 65◦C and transferred on ice to ensure
denaturation of RNA secondary structures. Thereafter the Reverse Transcription Mix
(Table 3.20) was added and the cDNA synthesis performed for 30 min at 55◦C. For
inactivation of the reverse transcriptase the sample was heated to 85◦C for 5 min and
then placed on ice. For further use the samples were stored at -20◦C.
Table 3.20.: Component mixture for cDNA synthesis (Transcriptor High Fidelity cDNA Synthesis Kit);
x, volume appropriate for 50 ng of total RNA was added
Template Primer Mix
Reagent Volume
Anchored-oligo(dt)18 Primer [50 pmol/µl] 1 µl
total RNA x
deionized water ad 11.4 µl
Reverse Transcription Mix
Reagent Volume
Reverse Transcriptase Reaction Buffer (x5) 4 µl
Protector RNase Inhibitor [40 U/µl] 0.5 µl
Deoxynucleotide Mix [10 mM each] 2 µl
DTT 1 µl
Reverse Transcriptase 1.1 µl
3.2.22. The 53BP1 Foci Assay
The 53BP1 assay performed in the present work is an immunostaining method using
a 53BP1 antibody for the visualization of nuclear foci that are localized at sites of DNA
DSBs [115].
The SCL-II cells were transfected as described in 3.2.15.1 with ∼ 100 kBq of I-125-TFO,
incubated for 20 - 23 h at 37◦C and then stored in freezing medium at -150◦C for decay
accumulation. As negative controls served SCL-II cells which were transfected with
the analog but unlabeled TFO [5 pmol], and further treated as the active transfected
cell samples. After the accumulation period the cells were thawed and the appropriate
number (5 x 104 cells/well) was plated in 6-well plates and grown on sterilized glass
coverslips for 20 - 23 h. Thereafter the cells were rinsed three times with PBS-Buffer
and fixed with 4% paraformaldehyde (solved in PBS) for 20 min at room temperature.
Then rinsed two times with TBP-Buffer. The coverslips were covered with 1% Triton
X-100 (solved in PBS) for 20 min at room temperature and then rinsed two times with
TBP-Buffer. Blocking was done in 5% goat serum (solved in PBS) for 1 h at room
temperature followed by two washing steps with TBP-Buffer. The primary antibody
(53BP1, H-300: sc-22760) was added in a 500-fold dilution in TBP-Buffer for 1 h at
46
3. Materials and Methods
room temperature followed by three washing steps with TBP-Buffer and incubation
for 45 min with the second antibody (1:700 in TBP-Buffer, goat anti-rabbit IgG-TR:
sc-2780). The coverslips were then washed two times in TBP-Buffer, once in PBS-
Buffer and finally rinsed in deionized water and kept at room temperature for drying.
For microscopy the monolayers were mounted with ProLong Goldantifade reagent with
DAPI on glass slides. The analysis was performed on a Zeiss LSM700 Observer Z1
microscope. For each sample 100 randomly selected cells were analyzed and the
average number of foci was calculated.
3.2.23. Colony Forming Assay
The Colony Forming Assay (CFA) is a method to determine the ability of a cell to
proliferate indefinitely, whilst retaining its reproductive ability to form a large colony
or a clone [92]. It is frequently used to measure the effect of ionizing radiation or
chemotherapeutic agents on the reproductive ability of cells [53].
In the present work the CFA was performed with SCL-II cells after gamma irradiation
(3.2.2), (I-125)IdU incorporation (3.2.16) and after the transfection with ∼ 100 kBq I-
125-TFOs (3.2.15.1) binding to single or multiple targets in the human genome. The
transfected cell samples were cultured for 20 - 23 h at 37◦C, trypsinized and then
stored in freezing medium for decay accumulation at -150◦C. For gamma irradiated
cells, storage was not necessary. As negative controls served SCL-II cells which were
transfected with the analog but unlabeled TFO [5 pmol], respectively, IdU or unirradi-
ated, and further treated as the active transfected or irradiated cell samples. After the
accumulation period the cells were thawed, centrifuged (5 min, 300 x g, RT; unless
specified all centrifugation steps were performed with this program) and the cell pellet
was resuspended in MEM. The appropriate number of cells (500 cells/well) was plated
in a 6-well plate, filled with 3 ml MEM each, and incubated for 12 days. Cell culture
medium was renewed after 6 days. After 12 days the culture medium was removed
and the cells were washed with 2 ml PBS. Then the cells were fixed by the addition of
methanol and incubated for 10 min at -20◦C. Thereafter the methanol was discarded
and the cells dried at room temperature for 10 min. After one more wash step with
PBS 10% Giemsa stain (preparation see 3.2.23.1) (1 ml/well) was added for 15 min at
room temperature. Finally the Giemsa stain was discarded and the cells were washed
twice in deionized water and then dried at room temperature. For the interpretation
each colony consisting of 50 or more cells was counted as survivor. The total num-
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ber of colonies divided by the total number of colonies of controls was defined as the
surviving fraction, which was then plotted against the accumulated decays per cell.
3.2.23.1. Preparation of Giemsa Stain
The Giemsa staining solution was prepared as follows. The desired amount of Giemsa
stock solution was mixed with Microscopy Buffer to the desired concentration and there-
upon the solution was filtered through a folded filter (grade 3 hw).
3.2.24. Micronucleus Assay
The micronucleus assay is a method for the quantification of chromosomal damage
resulting from genotoxic compounds like chemical agents or ionizing radiation. The
standard for the chromosomal damage used in this assay is the formation of micronu-
clei which are small cytoplasmic bodies containing a part or a whole chromosome.
The formation of micronuclei occurs after chromosomal damage within the anaphase,
when these chromosomal fragments or chromosomes are not carried to the opposite
poles. The micronuclei are also surrounded by a nuclear membrane and appear after
cytokinesis as small nuclei (micronuclei) in one of the daughter cells [49].
In the present work the micronucleus assay was used to determine the genotoxic po-
tential of I-125-TFOs in SCL-II cells. Therefore SCL-II cells were transfected, as de-
scribed in 3.2.15.1, with ∼ 100 kBq of the desired I-125-TFO or 5 pmol of the analog
unlabeled TFO serving as negative control. The transfected cells were cultured for 20
- 23 h at 37◦C, trypsinized and then aliquoted at 5x105 cells per freezer vial in freez-
ing medium. The samples were stored at -150◦C for decay accumulation. After the
accumulation period the cells were thawed, centrifuged (5 min, 300 x g, RT; unless
specified all centrifugation steps were performed with this program) resuspended in
MEM + Cytochalasin B [1 µg/ml] and cultured for 24 h at 37◦C. Thereafter the cells
were washed twice with PBS, trypsinized and resuspended in 1.5 ml MEM. The cell
solution was transferred into a 2 ml tube and centrifuged. The supernatant was dis-
carded and the cell pellet washed twice in PBS. For fixation the cells were resuspended
in a Methanol/ Acetic acid (3:1) solution and were stored at 4◦C for further use. For
micronucleus analysis 10 - 20 µl of the fixed cells were dropped with a pipet on micro-
scope slides and allowed to dry at RT. After that the slides were incubated in a Hoechst
33342 staining solution [1 µg/ml] for 1 min at RT and then transferred successively in
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two deionized water baths for 1 min each. After drying at RT the cells were embed-
ded in mounting medium on the microscope slide and covered with coverslips. The
samples were analyzed on a Zeiss Axioplan 2 microscope with the Metafer 4 Metacyte
Software.
3.2.25. Statistical Analysis
Results are expressed as the mean and the standard error of the mean (SEM) from
at least three (in exceptions two) independent experiments. Statistical analyses were
performed with Student´s two-tailed paired (or unpaired) t-test. Values of p < 0.05 were
considered statistically significant.
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4.1. In Vitro DNA Triplex Formation and Binding Assay
A total of 26 TFOs were tested for their triplex forming ability in vitro with their specific
target sequence. These TFOs were designed as described in 3.2.6 complementary
to their target sequences. The verification of the triplex formation was performed with
EMSA (3.2.5).
M 1 5 4 3 2 9 8 7 6 
! ! ! + + + - - - 
30 bp –  
20 bp –  
40 bp –  

Figure 4.1.: Triplex formation in vitro visualized with the electrophoretic mobility shift assay (EMSA).
Silver staining. 20% native polyacrylamid gel. •: Non-sense samples containing the target
sequence with a non-complementary TFO as control; lanes 1, 4 and 7. +: TFOs with their
specific target sequences; lanes 2, 5 and 8. -: Negative controls containing the specific
TFO target fragment only; lanes 3, 6 and 9. M: Marker. A band shift reflects a DNA triplex
formation ().
Of all tested TFOs (Table 4.1) having a suitable sequence to form a DNA triplex with
their specific DNA targets about 58% failed to form a triplex in the EMSA in vitro. Suc-
cesful DNA triplex formation could be verified for 42% and was indicated by a clear
band-shift of the Target/TFO construct as shown on Figure 4.1 (lane 5, ) when com-
pared to the target sequence only (Figure 4.1, lane 6). The triplex formation with non-
complementary (non-sense) TFOs as a proof for the specificity of the specific TFO and
its target sequence was also analyzed. As expected all non-sense TFOs failed to form
DNA triplices (Figure 4.1, lane 1, 4 and 7).
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Table 4.1.: Triplex-Forming-oligonucleotides tested in the present work. TFO with confirmed triplex
formation are marked in gray.
Name Sequence (5´- 3´)
TFO-V1 ggt ttg gtg gtt ggg tgt gtg
TFO-V2 ttt gtt ggg tgg tgg gtt ggt tgt gtt aag aaa
TFO-V3 ggg ggt tgg ggt gtg gtg ggg
TFO-V4 ggg ggt tgt ggt ttg tgg ttg ttg
TFO-V5 ggtt gtg tgt gtg tgt gtg
TFO-V6 ttg tgg gtg tgg tgg ggt tt
TFO-V7 gtt gtg gtt gtg gtt ggg
TFO-V8 ggt gtt ggt tgg ttg ttt tgg tgg gga aga gg
TFO-BCL2 gtg ttt gtt ttt gtt ggg tgg tgt ggg gc
TFO-BRCA1 tgg gtg tgt gtt ggt gtg ttg ttc cgg ga
TFO-V11 tgg gtg gtg ggt gtt tgt tgt g
TFO-V12 ggg tgg tgt ggg tgg gtt ttt ttt ggg
TFO-V13 ggg ttt ttt gtg ggg gtg ttg
TFO-V14 ttg tgc ttt ggt tgt
TFO-V15 ttg tgc ttt ggt tgt
TFO-V16 ttg gtt cgg gtt gg
TFO-V17-Cyt-17 tgg tgg ttt gtg ggt tc
TFO-GAPDH ggg ggt ggg gtt tgt ttg ttt c
TFO-V19-Cyt-1423 tgt ttt ggg ttg gct tgt tgg tcg
TFO-V20-Cyt-12 ggt ggt tgg ttc ggt tgg t
TFO-V21-Cyt-20 ttt tgt ggt gtt gtt ttg gcg tt
TFO-V23-Cyt-81729 ttg tgt tcg ttt gtt gcg ttt gtg ggt tct
TFO-V25-Cyt-18 ggg ggt ttg tgg ttt ttc
TFO-V26-Cyt-19 ggg tgg ttg gtt ggg ttg c
TFO-V27 ttt ggt ttt ggg ggg ttt ggt tgg
TFO-V28 gtg ttg ttt gtg ggt tgt ggg t
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4.2. I-125 Labeling of TFOs
After having examined the triplex forming capabilities of the unlabeled TFOs (4.1) the
next major step was to establish the I-125-labeling of the TFOs. The labeling reaction
was performed with a modified version of the Primer Extension Method published by
Panyutin et al. [97]. However, several delicate steps in the labeling reaction, which are
thoroughly described in this chapter, had to be adapted and improved.
4.2.1. Denaturation
During the first two steps of the labeling reaction the biotin template and preTFO were
annealed and the preTFO was elongated with a single I-125dCTP (3.2.8). In order to
isolate the now I-125-labeled TFO from the biotin template, the TFO-Template com-
plex had to be denatured. For denaturation the most common method is heating to a
temperature above the melting temperature (Tm) of the TFO. Denaturation can also be
achieved by applying alkaline conditions through the addition of NaOH. To determine
the best denaturation conditions the primer extension was performed with FITC-dCTP,
and thereafter the FITC-labeled TFO-Template-Biotin complex (Figure 4.2), bound to
streptavidin magnetic particles, was successively heated and brought to alkaline con-
ditions for different periods of time.
– Streptavidin 
– Biotin 
Magnetic 
Particle 
– FITC FITC-labeled TFO (20 bp) 
Template-Biotin (35 bp) 
– hydrogen Bonds 
Figure 4.2.: Schematic diagram of the FITC-labeled TFO-Template-Biotin complex bound to a strepta-
vidin magnetic particle.
After each denaturation step the magnetic particles were sedimented with a magnet
and the supernatant was collected and loaded on a 20% polyacrylamidgel. Before the
next denaturation the magnetic particles were resuspended in deionized water respec-
tively NaOH solution. After the gel run the apparent running height of the EtBr stained
fragments revealed the efficiency of the applied denaturation conditions (Figure 4.3).
The FITC-labeled TFO-Template complex was expected to run at approximately 35
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bp whereas the FITC-labeled TFO alone should be detectable at ∼ 20 bp. Thus an
EtBr- and FITC-signal at 35 bp indicated a breakup of the streptavidine-biotin bond
and therefore TFO-template complex could be detected in the supernatant. An EtBr-
and FITC-signal at 20 bp was evidence for the efficient detachment of the TFO from
the template.
a) EtBr!Staining b) FITC-Fluorescence 
M#
30 bp – 
20 bp – 
40 bp – 
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5 min + 
79°C 
5 min + 
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5 min  + 
NaOH 
5 min 
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79°C 
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5 min + 
79°C 
5 min + 
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5 min  + 
NaOH 
5 min 
Figure 4.3.: Polyacrylamidgel-electrophoresis of FITC-labeled TFO-Template complex samples after
treatment at different denaturation conditions; lanes 1 - 5. M: Marker. The same sample
was successively analyzed at each condition. a) Ethidium bromide staining and b) FITC
signal scan. 20% native polyacrylamidgel.
At denaturation conditions of 79◦C for 3 min (Figure 4.3, lane 1) signals at 20 and 35
bp were detectable but were very weak. Further incubation at 79◦C for additional 5
min (Figure 4.3, lane 2) increased the intensity of both signals with a more pronounced
signal at 35 bp. An additional incubation at the same conditions (Figure 4.3, lane
3) increased both signals only slightly. Incubation in 0.15 M NaOH solution (Figure
4.3, lane 4) led to a pronounced signal at 20 bp and no detectable signal at 35 bp.
Additional 5 min of incubation at the same conditions (Figure 4.3, lane 5) showed the
opposite, with a signal at 35 bp and no detectable signal at 20 bp. This observation
is conform with the manufacturer´s informations admitting that small amounts of the
biotin-template can be released after incubation at alkaline conditions. However, due
to the good harvest rate the denaturation of all labeled TFOs from the templates used
in this study was performed at alkaline condition by the addition of 0.15 M NaOH for 5
min. Before further use the isolated TFOs had to be titrated to a neutral pH-value by
the addition of 10 x TFO-Binding Buffer and 1.25 M acetic acid.
4.2.2. Labeling Efficiency
The labeling efficiency was calculated as the ratio of preTFO amount in the primer
extension mix and the amount of I-125-labeled TFOs at the end of the reaction.
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The primer extension reaction mix described in 3.2.8 using 5 pmol of preTFO, 5 pmol
of template and 2.5 MBq of I-125-dCTP led to an average total activity of ∼ 370 kBq
in TFOs labeled with a single I-125-dC at the terminal 3‘-position. According to the
calculation formulas shown in 3.2.9 this equaled a labeling efficiency of ∼ 90% and a
total amount of I-125-labeled TFO of ∼ 4.5 pmol, respectively. In addition, the influence
of an increased amount of preTFO/template was examined. Therefore, a maximum of
100 pmol of preTFO/template per reaction mix was tested. This increase of preTFO
led to a total amount of I-125-labeled TFO of approximately 11 pmol and 11% labeling
efficiency. Thus a 20-fold increase of preTFO/template amount resulted in an approx-
imate doubling of I-125-labeled TFO. At the same time, however, the total amount of
unlabeled TFO at the end of the reaction was more than 170-fold (0.5 pmol to 89 pmol)
increased. Due to this unfavorable ratio of labeled to unlabeled TFO the primer exten-
sions in the present work were performed with the reaction mixture described in the
first place.
4.2.3. TFO Triplex Formation after I-125 Labeling
After primer extension the I-125-labeled TFOs were examined in vitro for their triplex
forming capabilities.
1000 bp – 
2000 bp – 
1500 bp – 
2 M 2 
b) Autoradiography a) EtBr-Staining 
1 1 
Figure 4.4.: Triplex formation of I-125-labeled TFO-BCL2, visualized via a) gel electrophoresis com-
bined with b) autoradiography. 3.5% polyacrylamidgel. Lane 1: I-125-labeled TFO + ∼ 0.4
µg target fragment (1695 bp, C). Lane 2: Non-sense sample containing a non comple-
mentary I-125-labeled TFO + ∼ 0.4 µg target fragment (1695 bp, C).
The gel electrophoresis (Figure 4.4 a) combined with the autoradiographic analysis
(Figure 4.4 b) confirmed successful triplex formation for TFOs after I-125 labeling with
the specific DNA target (Figure 4.4 a, lane 1 and b, lane 1). Due to the target length of
1695 bp an EMSA is not possible as a band shift caused by DNA triplex formation would
not be pronounced enough for being visualized. However, the signal in the autoradio-
graphy revealed that the I-125-labeled TFO had bound to its specific target sequence
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(Figure 4.4 b, lane 1). As expected the non-complementary I-125-labeled TFO failed
to form a triplex with the target fragment, having led to no detectable autoradiographic
signal (Figure 4.4 b, lane 2).
100 bp – 
300 bp – 
200 bp – 
2 M 2 
b) Autoradiography a) EtBr-Staining 
1 1 
Figure 4.5.: Triplex formation of I-125-labeled TFO-BCL2 with varying target concentrations, visual-
ized via a) electrophoretic mobility shift assay combined with b) autoradiography. 12%
polyacryamidgel. Lane 1: I-125-labeled TFO + 1.6 µg target fragment (212 bp). Lane 2:
I-125-labeled TFO + 4.9 µg target fragment (212 bp). M: Marker. A band shift and an au-
toradiographic signal, respectively, reflects a DNA triplex formation (). Target fragment
(C).
EMSA with the same TFO but with a much smaller target fragment (Figure 4.5,C, 212
bp), used at two different concentrations (lane 1, 1.6 µg; lane 2, 4.9 µg), revealed the
successful DNA triplex formation by a band shift. The detected band shift in Figure 4.5
a, lane 1 and 2 () was additionally confirmed by the signals in the autoradiographic
assay in Figure 4.5 b, lane 1 and 2 (), showing successful binding of I-125-labeled
TFO to its target. The variation in signal strength in the EtBr staining and the autoradio-
graphy was in good accordance with the different amounts of target fragments loaded
in the reaction mixes (1.6 µg lane 1, 4.9 µg lane 2).
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4.3. DNA Double-Strand Break Analysis in vitro
To demonstrate that I-125-labeled TFO induced DSBs within the binding region, a 1695
bp target fragment with a specific binding site for TFO-GAPDH was used for analysis.
After 143 days at -80◦C for decay accumulation the DNA triplex was analyzed on an
agarose gel and visualized with EtBr staining (3.2.4) and southern blotting (3.2.13).
The TFO binding site and induced breakage fragments of I-125-TFO-GAPDH are dis-
played in Figure 4.6.
1695 bp 
1014 bp 681 bp 
I-125!
DNA fragment 
Breakage fragments 
    5´-GGGGGTGGGGTTTGTTTGTTTC-´3 I-125-I-TFO-GAPDH !!
    3´-GGGGGAGGGGAAAGAAAGAAAG-´5 Target rev. 
    5´-CCCCCTCCCCTTTCTTTCTTTC-´3 Target fwd.!
Figure 3 
Figure 4.6.: Schematic diagram of the 1695 bp long DNA fragment containing the target sequence for
TFO-GAPDH and the two expected breakage fragments of 681 bp and 1014 bp length.
The TFO is I-125-labeled at the 3‘-terminal cytosine and binds to the polypurine target
sequence in reverse Hoogsteen orientation.
The results of the DSB analysis revealed that the I-125-TFO-GAPDH induced a single
DSB within the 1695 bp target fragment (Figure 4.7 a,C) resulting in the two expected
breakage fragments of 1014 bp and 681 bp (Figure 4.7 a, ). No DNA breakage was
observed for the non-binding, non-specific, non-sense I-125-labeled TFO (Figure 4.7
a, lane 2). Southern blot analysis (Figure 4.7 b) verified that the observed breakage
fragments originated from the target fragment (Figure 4.7 b, lane 1). The southern blot
probes were P-32-labeled PCR amplificates of the region up- and downstream of the
TFO target site (3.2.12). The two detected bands at 500 bp and below did not show
a southern-blot signal and are likely to be unspecific amplificates from the PCR of the
target fragment.
The breakage efficiency in the target fragment was calculated as the sum of the band
intensities of the two breakage fragments to the sum of the intensities of all three
fragments according to Sedelnikova et al. [117] leading to a percentage of breaks
of ∼ 40% after 143 days of decay accumulation (∼ 1.9x1011 decays/pmol target DNA).
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a) EtBr-Staining b) Southern-Blot 
M 1 2 1 2 
500 bp – 
1000 bp – 
2000 bp – 
1500 bp – 
Figure 4.7.: DSB analysis of a 1695 bp DNA fragment (C) containing the target sequence for TFO-
GAPDH. The samples were separated in a 1% agarose gel and visualized by a) ethidium
bromide staining and b) southern blotting. M: Marker. Lane 1: Target fragment + I-125-
TFO-GAPDH. Lane 2: Non-sense sample containing the target fragment + non-binding
I-125-TFO. Breakage fragments () of 1041 and 681 bp length. Figure according to Dah-
men and Kriehuber [23]
That equaled ∼ 1.9x1011 decays in 6 x 1011 molecules (0.31 decays/molecule). At ∼
40% breaks this would be ∼ 1.2 DSB/decay. Taken into account that the molar ratio
TFO:DNA target in the reaction was 2:1 (3.2.13), the number of DSB per decay was
reduced to ∼ 0.6 DSB/decay because only half of the TFOs could bind to the DNA
target at all.
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4.4. Biokinetic of TFOs in SCL-II Cells
To elucidate the biokinetic behavior of TFOs, and to verify that the chosen transfec-
tion method (3.2.15.1) was able to get TFOs directly into the cell nucleus as well as
to investigate whether the transfected TFOs persist for a longer period in the nucleus,
biokinetic studies were performed in SCL-II cells. Therefore SCL-II cells were trans-
fected with Alexa488-labeled TFOs and then whole cells and isolated nuclei samples
were analyzed in the flow cytometer after certain time points during the 72 h post trans-
fection. All samples whose measured fluorescence exceeded a defined threshold were
defined as TFO positive cells and TFO positive nuclei, respectively. The threshold was
set on the background fluorescence measured in sham transfected negative control
samples (Figure 4.8). It should be kept in mind, however, that due to the sensitivity
limit of the flow cytometry [148], cells or nuclei that are defined as TFO negative can
still contain a certain amount of TFOs.
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Figure 4.8.: Flow cytometric histogram of SCL-II cell analysis after transfection with an Alexa488-
labeled TFO. Threshold setting (vertical black lines) for a) cells and b) nucleic samples
on basis of the background fluorescence in sham transfected negative controls. Number
of cells and cell nuclei, respectively, plotted against the Alexa488 fluorescence. The inte-
gral signal in the isolated nuclei shows stronger signal in comparison to the analyzed cells
due to analysis at higher signal amplification.
The flow cytometric analysis showed that Alexa488-labeled TFOs were distributed
throughout the cells immediately after transfection. One h post-transfection TFOs could
be detected in whole cell samples and in isolated nuclei (Figure 4.9). A transfection
efficiency of 85% ± 1.5% in whole cells and 75% ± 15.4% in isolated cell nuclei was
observed. Within the first 6 h post-transfection a significant loss of TFO positive cell
nuclei down to ∼ 21% ± 8.1% occurred, followed by an almost constant fraction of TFO
positive nuclei up to 24 h. After 30 h post transfection a slow decline of TFO positive
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nuclei was detected continuing until 72 h. The TFO positive cells did not show a sig-
nificant alteration for 30 h after transfection, followed by a significant decrease of TFO
positive cells up to 72 h post transfection. The percentage of apoptotic/ necrotic cells
did not change significantly throughout the entire test period.
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Figure 4.9.: Flow cytometric analysis of SCL-II cells after transfection with Alexa488-labeled TFO
(n=3). Cell and nucleic samples were prepared for flow cytometric analysis after different
time points (1 h - 72 h). Percent of TFO positive cells (green bar, left axis) and cell nuclei
(red bars, left axis) plotted against time after transfection. Fraction of apoptotic/ necrotic
cells in TFO transfected cells (black line, right axis) plotted against time after transfection.
Error bars indicate the standard error of the mean (SEM) of n=3 independent experiments.
(*p-value < 0.05; when not indicated differently samples were compared to 1 h sample)
Beside the flow cytometric analysis transfected SCL-II cells were also microscopically
examined via live cell imaging.
The live cell imaging was performed in 20 cells per experiment for 22 h, while pictures
were taken every 2 h of the individual cells. The images were analyzed by comparing
the percentage of cells showing TFO signals in the cytoplasm only (Figure 4.10, 6 h/20
h, right pictures) to cells showing signal both in the cytoplasm as well as in the nucleus
(Figure 4.10, 6 h/20 h, left pictures). The analysis revealed that the percentage of both
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Figure 4.10.: Live cell images of SCL-II cells 6 h and 20 h after transfection with Alexa594-labeled
TFOs (red). For visualization the SCl-II cells were kept in a microscope incubation
chamber, enabling live cell images. (DIC overlay with fluorescence microscopy; Zeiss
Plan-Apochromat 100x/1.40 Oil DIC, Texasred T7 Filter)
cell groups was almost constant throughout the whole testing period. The percentage
of cells with TFOs in the cytoplasm only was 79% ± 3%. Cells with TFO signals in the
cytoplasm and nucleus showed on average a percentage of 21% ± 3%. Additionally, it
has to be stated that none of the cells with TFO signal in the cytoplasm and the nucleus
retained the nuclear signal throughout the 22 h of observation. Interestingly, a steady
loss or gain of TFO signal in the nucleus was detected. The longest period of time with
a constant TFO signal in the nucleus was detected for 14 h (Figure 4.11). After 16 h
the nucleus was not perfectly visible but after 18 h the TFO signal was located in the
cytoplasm only, not in the nucleus anymore. The average signal in the nucleus was
detectable for approximately 4 h.
10 µm10 µm10 µm10 µm
10 µm10 µm10 µm10 µm10 µm
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Figure 4.11.: Live cell images of a single SCL-II cell after transfection with Alexa594-labeled TFOs
(red). Time period of 22 h with pictures taken every two hours. (DIC overlay with fluores-
cence microscopy; Zeiss Plan-Apochromat 100x/1.40 Oil DIC, Texasred T7 Filter)
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4.5. Induction of DNA Double-Strand Breaks
The 53BP1 assay was performed in addition to the CFA (4.6.1) and was used to visu-
alize and quantify the DSBs in SCL-II cells after transfection with I-125-TFO-GAPDH,
I-125-TFO-MBS and I-125-TFO-QRT (Figure 4.12). For the subsequent decay accu-
mulation cells were stored at -150◦C. Cells transfected with the corresponding unla-
beled TFO served as negative controls.
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
5 
0 200 400 600 800 1000 
Fo
ci
/C
el
l 
Decays/Cell 
I-125-TFO-
MBS 
I-125-TFO- 
QRT 
I-125-TFO-
GAPDH 
a) b) 
10 µm 
Figure 4.12.: DSB detection as 53BP1 foci in SCL-II cells after transfection with I-125-TFOs. a) Micro-
scopic visualization of DSBs in SCL-II cells by 53BP1-antibody staining (DSBs, red) and
DAPI staining (Nucleus, blue). b) 53BP1 foci on average per SCL-II cell plotted against
accumulated decays/cell after the transfection with I-125-TFO-MBS (_, —), I-125-TFO-
QRT (, – – – ) and I-125-TFO-GAPDH (4, - - - - ). Negative controls (not displayed)
were transfected with the corresponding unlabeled TFO and showed on average ∼ 0.8
foci/cell. The experimental points were fitted with linear multi target trend lines. Figure
according to Dahmen and Kriehuber [23]
The negative controls showed with increasing storage time at -150◦C an increase of
foci/cell. Within the first days of storage the foci/cell increased from 0.5 foci/cell to a
maximum of 1 focus/cell, where they remained constant for the rest of the storage pe-
riod (∼ 0.8 foci/cell). The transfection with the single-binding-site TFO-GAPDH, which
has its target sequence in the GAPDH gene, led to a linear increase of foci signals (y
= 0.0046x + 0.8; R2 = 0.89) reaching 3 foci/cell at approximately 480 accumulated
decays/cell. The cells transfected with the multi-binding-site I-125-TFO-MBS, which
possesses approximately 7000 targets in the whole genome, showed a very similar
increase of foci numbers (y = 0.0049x + 0.8; R2 = 0.71) reaching 3 foci/cell at ap-
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proximately 450 accumulated decays/cell. In contrast, I-125-TFO-QRT, which targets
∼ 370.000 putative target sequences induced a more pronounced increase of foci per
decay (y = 0.0076x + 0.8; R2 = 0.86) with 3 foci/cell at ∼ 300 accumulated decays/cell
resulting in ∼ 1.5 fold stronger foci induction per decay.
Beside the quantification of the 53BP1 foci at different amounts of accumulated de-
cays/cell (Figure 4.12), also the percentage of cells harboring a certain quantity of foci
at a dedicated amount of accumulated decays/cell was determined (∼ 330 decays/cell,
Figure 4.13).
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Figure 4.13.: Frequencies of 53BP1 foci in SCL-II cells after transfection with I-125-TFO-MBS (blue,
n=3), I-125-TFO-QRT (red, n=3) and I-125-TFO-GAPDH (green, n=3); Negative controls
(purple, n=3). The foci frequencies were determined after decay accumulation in the
cells up to ∼ 330 decays/cell. The bars show the percentage of cells (y-axis) containing
the indicated number of foci (x-axis). Error bars indicate the standard error of the mean
(SEM) of n=3 independent experiments. (*p-value < 0.05)
The negative controls contained in 51% ± 10% of the cells no foci. In 40% ± 5%
and 43% ± 11% of the cells transfected with I-125-TFO-MBS and I-125-TFO-GAPDH,
respectively, no foci were found. In cells transfected with I-125-TFO-QRT only 28% ±
6% of the cells contained no foci. A number of foci ranging from 1 - 2 foci/cell was
detected in 36% ± 5% of the negative controls and in ∼ 24% of cells after transfection
with each individual of the three TFOs. Approximately 20% ± 4% of the cells contained
3 - 5 foci/cell regardless which TFO was used, whereas 11% ± 4% of the negative
controls showed 3-5 foci/cell. In 10% ± 3% of I-125-TFO-MBS and I-125-TFO-GAPDH
transfected cells and in 14% ± 3% of the I-125-TFO-QRT transfected cells an amount
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of 6 - 8 foci/cell was found, which equaled an ∼ 1.4-fold higher percentage in the I-125-
TFO-QRT transfected cells. Only 2% ± 2% of the negative controls contained 6 foci/cell
or more. At 9 - 11 and 12 - 14 foci/cell the I-125-TFO-QRT displayed a ∼ 2-fold higher
percentage of cells when compared to the I-125-TFO-MBS and I-125-TFO-GAPDH
transfected cells.
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4.6. Cell Killing
4.6.1. Cell Killing of SCL-II Cells after Transfection with I-125-labeled
TFO
The CFA was performed to determine the cytotoxicity of I-125-labeled TFOs in respect
to number and quality of the targeted TFO binding sites. For decay accumulation sam-
ples were stored at -150◦C.
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Figure 4.14.: Cell survival curves of SCL-II cells after transfection with I-125-TFO-MBS (_, —), I-125-
TFO-GAPDH (4, - - - - ) or I-125-TFO-QRT (, – – –). Surviving fraction is plotted against
the amount of accumulated decays/cell. For decay accumulation the transfected samples
were stored at -150◦C. The data points were best fitted with the exponential multi target
model of cell survival. Figure according to Dahmen and Kriehuber [23]
The CFA of SCL-II cells showed a reduced cell survival in respect to accumulated
decays/cell for all three investigated I-125-labeled TFOs (Figure 4.14). The survival
data were best fitted by using the straight exponential model of cell survival. The
survival curve of I-125-TFO-GAPDH (y = e−0.0029x;R2 = 0.96) and I-125-TFO-MBS (y =
e−0.0026x;R2 = 0.76) showed a D37 value of ∼ 350 respectively ∼ 390 decays/cell. I-
125-TFO-GAPDH binds to a single site in the GAPDH gene only and the I-125-TFO-
MBS binds to ∼ 7000 target sites in the whole genome [121]. I-125-TFO-QRT, as well
a multiple target binding TFO applying the highest overall target number (∼ 370,000
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putative binding regions [133]) of all tested TFOs, induced a pronounced reduction of
cell survival (y= e−0.0044x;R2 = 0.44), showing a D37 value of ∼ 220 decays/cell, resulting
in an almost 2-fold increase of cell killing when compared to I-125-TFO-GAPDH and
I-125-TFO-1 Cyt 34.
4.6.2. Cell Killing of SCL-II Cells after (I-125)IdU incorporation
In order to compare the cyotoxicity of I-125-labeled TFOs with DNA incorporated I-
125, CFAs of SCL-II cells after (I-125)5-Iodo-2´-deoxyuridine ((I-125)IdU) incorporation
were carried out. The thymidine analogon used as a carrier for I-125 was incorporated
during S-phase into the DNA. Therefore most of the decays occured in the DNA. After
incorporation of (I-125)IdU cells were stored for decay accumulation at -150◦C.
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Figure 4.15.: Cell survival curve of SCL-II cells after incorporation of (I-125)IdU (n=3). Survival fraction
is plotted against the number of accumulated decays/cell. For decay accumulation the
samples were stored at -150◦C. The data points were best fitted with the straight expo-
nential single multi target model of cell survival. Error bars indicate the standard error of
the mean (SEM) of n=3 independent experiments.
The SCL-II cells showed a pronounced reduction of cell survival (y= e−0.0041x;R2 = 0.98)
after incorporation of (I-125)IdU in relation to the accumulated decays. The D37 value
was reached at ∼ 239 decays/cell and at more than 575 decays/cell the survival fraction
was below 0.1. The data were best fitted using the exponential multi target model of
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cell survival, resulting in a linear shaped survival curve, characteristic for high-LET
radiation.
4.6.3. Cell Killing of SCL-II Cells after γ-Irradiation
SCL-II cells were γ-irradiated in T25 cell culture flasks at doses of 1, 2, 3, 4, 6, 8 and
10 Gy (3.2.2). The aim was to generate a dose dependent survival curve after gamma
irradiation for comparison with the survival data after Auger irradiation (4.6.1).
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Figure 4.16.: Cell survival curves of SCL-II cells after gamma irradiation (n=3). Survival fraction plotted
against the applied dose. The experimental points were fitted with the two-component
model of cell survival. Error bars indicate the standard error of the mean (SEM) of n=3
independent experiments.
SCL-II cells showed a typical low-LET type of survival curve after gamma irradiation
(Cs-137, 0.7 Gy/min). The survival data were fitted best using the two-component
model of cell survival (Dq = 1.5, D0 = 2 Gy, n = 2). The D37 value was reached at
approximately 3.5 Gy (Figure 4.16). At 7.4 Gy the survival fraction was below 0.1.
Higher doses led to a linear decrease of the survival fraction until no surviving cells (≤
0.01) could be detected at 10 Gy. The shape of the survival curve was, with the initial
slope at low-dose, characteristic for low-LET radiation.
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In order to allow a comparison of all survival data (Figure 4.17) the applied doses for
I-125-TFO and (I-125)IdU transfected cells were determined with Point-Kernel calcu-
lations after Humm et al. [58] for SCL-II cells with a cell nucleus diameter of 10 µm.
These led to an estimated dose of 3.5 mGy per decay of I-125. The I-125 data were
best fitted with the exponential multi target model of cell survival and the data after
γ-irradiation with the two-component model. All I-125 irradiated cells displayed a lin-
ear and more pronounced decrease in cell survival when compared to the γ-irradiated
cells. The cytotoxic effect of DNA incorporated (I-125)IdU was very similar to the multi-
binding-site I-125-TFO-QRT.
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Figure 4.17.: Cell survival curves of SCL-II cells after transfection with I-125-TFO-MBS (_, —), I-125-
TFO-GAPDH (4, - - - - ) and I-125-TFO-QRT (, – – –). Incorporation of (I-125)IdU (•,–
· · –) and Gamma Irradiation (◦, —). Survival fraction plotted against the applied dose.
Point-Kernel dose calculation for I-125-TFO-MBS, I-125-TFO-GAPDH, I-125-TFO-QRT
and (I-125)IdU transfected cells after Humm et al. [58] for SCL-II cells with a cell nucleus
diameter of 10 µm; 1 decay ∼ 3.5 mGy
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4.7. Relative Gene Expression Analysis
The relative gene expression analysis was performed by qRT-PCR (3.2.20) of RNA
isolates from SCL-II cells after transfection with I-125-labeled TFOs (3.2.15.1). Prior to
RNA isolation the transfected cells were stored for decay accumulation until ∼ 300 ac-
cumulated decays/cell were obtained. The aim of the study was to determine the effect
of I-125-labeled TFOs on the gene expression of the respective targeted gene. Three
different TFOs were designed, specific for the genes GAPDH, BRCA1 and BCL2.
4.7.1. GAPDH Gene Expression
TFO-GAPDH was designed to bind within the GAPDH gene. The target sequence
is located in the promoter region, 422 bp upstream of the GAPDH sequence (Figure
4.18 b). The relative gene expression of GAPDH showed a significant 1.7-fold down-
regulation in I-125-TFO-GAPDH transfected SCL-II cells in comparison to the negative
control cells which were transfected with non-labeled TFO-GAPDH (Figure 4.18 a).
When compared to I-125-TFO-QRT the I-125-TFO-GAPDH transfected cells showed a
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    5´-GGGGGTGGGGTTTGTTTGTTTC-´3 I-125-TFO-GAPDH !!
    3´-GGGGGAGGGGAAAGAAAGAAAG-´5 Target rev. 
   5´-CCCCCTCCCCTTTCTTTCTTTC-´3 Target fwd.!
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Figure 4.18.: a) Relative gene expression of GAPDH after transfection with I-125-TFO-GAPDH (n=7),
I-125-TFO-QRT (n=3) and unlabeled TFO-GAPDH (n=3) as negative control. The (I-125-
)TFO-GAPDH binds to a single target sequence in the GAPDH gene. I-125-TFO-QRT
binds to multiple targets in the whole human genome. b) Schematic diagram of the
TFO-GAPDH target sequence and its location in the GAPDH gene. Error bars indicate
the standard error of the mean (SEM) of n independent experiments. (*p-value < 0.05).
Figure according to Dahmen and Kriehuber [23]
significant 1.4-fold down-regulation of GAPDH expression. In contrast, the I-125-TFO-
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QRT transfected cells displayed a non-significant 1.1-fold reduced expression when
compared to the negative control.
4.7.2. BRCA1 Gene Expression
TFO-BRCA1 was designed to bind within the BRCA1 gene. The target sequence is
located on the forward strand within the region of intron 19 at 6820 bp upstream of the
stop codon (Figure 4.19 b). The relative gene expression of BRCA1 showed no sig-
nificant alteration in I-125-TFO-BRCA1 transfected SCL-II cells when compared to the
negative control cells, which were transfected with non-labeled TFO-BRCA1 (Figure
4.19 a). In contrast SCL-II cells transfected with I-125-TFO-QRT showed a significant,
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Figure 4.19.: a) Relative gene expression of BRCA1 after transfection with I-125-TFO-BRCA1 (n=4),
I-125-TFO-QRT (n=3) and unlabeled TFO-BRCA1 (n=3) as negative control. The (I-125-
)TFO-BRCA1 binds to a single target sequence in the BRCA1 gene. I-125-TFO-QRT
binds to multiple targets in the whole human genome. b) Schematic diagram of the TFO-
BRCA1 target sequence and its location in the BRCA1 gene. Error bars indicate the
standard error of the mean (SEM) of n independent experiments. (*p-value < 0.05)
more than two-fold down-regulation of the BRCA1 expression. Compared to the nega-
tive control as well as to the I-125-TFO-BRCA1 transfected cells.
4.7.3. BCL2 Gene Expression
TFO-BCL2 was designed to bind within the BCL2 gene. The target sequence is lo-
cated on the forward strand within the region of intron 2 at 5422 bp downstream of
the BCL2 promoter region (Figure 4.20 b). The relative gene expression of BCL2 in
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I-125-TFO-BCL2 transfected cells showed a significant, almost two-fold up-regulation
when compared to the negative controls, transfected with non-labeled TFO-BCL2 (Fig-
ure 4.20 a). In contrast the BCL2 expression in SCL-II cells transfected with I-125-
TFO-QRT was approximately reduced to one fourth of the expression in the negative
controls and compared to the I-125-TFO-BCL2 transfected cells the BCL2 expression
was almost reduced by the factor of 10.
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Figure 4.20.: a) Relative gene expression of BCL2 after transfection with I-125-TFO-BCL2 (n=8), I-
125-TFO-QRT (n=3) and unlabeled TFO-BCL2 (n=3) as negative control. The (I-125-
)TFO-BCL2 binds to a single target sequence in the BCL2 gene. I-125-TFO-QRT binds
to multiple targets in the whole human genome. b) Schematic diagram of the TFO-BCL2
target sequence and its location in the BCL2 gene. Error bars indicate the standard error
of the mean (SEM) of n independent experiments. (*p-value < 0.05)
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4.8. Induction of Micronuclei
The micronucleus assay was performed to determine to what extent I-125-TFO-induced
DSBs were translated into chromosomal damage. Therefore, SCL-II cells were trans-
fected with I-125-TFO-GAPDH, I-125-TFO-QRT or I-125-TFO-MBS and stored for ac-
cumulation of ∼ 300, ∼ 400, ∼ 500 and ∼ 600 decays/cell at -150◦C. Cells transfected
with the corresponding unlabeled TFO served as negative controls. Additionally, the
MN induction after γ-irradiation was analyzed.
4.8.1. I-125-TFO-GAPDH Induced Micronuclei
SCL-II cells transfected with I-125-TFO-GAPDH showed a total amount of MN per 100
binuclear cells ranging between ∼ 14 ± 6.6 at ∼ 300 decays/cell and 8 ± 7.5 micronuclei
at ∼ 600 decays/cell (Figure 4.21). Only at ∼ 300 and ∼ 400 decays/cell the detected
number of MN per 100 binuclear cells was significantly increased when compared to
the negative controls with on average 4.8 ± 2 MN.
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Figure 4.21.: Micronuclei in SCL-II cells after transfection with I-125-TFO-GAPDH (n=3). Before anal-
ysis decays were accumulated by storage at -150◦C to ∼ 300, ∼ 400, ∼ 500 and ∼ 600
decays/cell. Total amount of micronuclei per 100 binuclear cells plotted against the ac-
cumulated decays/cell. Error bars indicate the standard error of the mean (SEM) of n=3
independent experiments. t-Test irradiated cells vs. non irradiated negative control (*p-
value < 0.05)
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4.8.2. I-125-TFO-QRT Induced Micronuclei
SCL-II cells transfected with I-125-TFO-QRT contained at each decays/cell significantly
more MN than the negative control harboring on average 2.4 ± 1 MN per 100 binuclear
cells (Figure 4.22). At ∼ 300 decays/cell the cells contained on average 21.4 ± 2.2 MN
per 100 binuclear cells but showed a decreasing number of MN with increasing de-
cays/cell. The most pronounced decrease was observed at ∼ 400 decays/cell with the
MN amount dropping to 12.3 ± 11.2 MN per 100 binuclear cells, and further decreasing
to a minimum of 7.6 ± 6.9 MN at ∼ 600 decays/cell.
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Figure 4.22.: Micronuclei in SCL-II cells after transfection with I-125-TFO-QRT (n=2). Before analy-
sis decays were accumulated by storage at -150◦C to ∼ 300, ∼ 400, ∼ 500 and ∼ 600
decays/cell. Total amount of micronuclei per 100 binuclear cells. Error bars indicate the
standard error of the mean (SEM) of n=2 independent experiments. t-Test irradiated cells
vs. non irradiated negative control (*p-value < 0.05)
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4.8.3. I-125-TFO-MBS Induced Micronuclei
SCL-II cells transfected with TFO-MBS contained at each decays/cell significantly more
MN than the negative control harboring on average 3.4 ± 2.8 MN per 100 binuclear
cells (Figure 4.23). The total amount of MN was almost constant between ∼ 300 to ∼
500 decays/cell with MN numbers from 13.8 ± 6.3 MN to 13.1 ± 11.4 MN. The highest
amount of MN was detected after ∼ 600 decays/cell with 20.5 ± 14.5 MN per 100
binuclear cells.
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Figure 4.23.: Micronuclei in SCL-II cells after transfection with I-125-TFO-MBS (n=3). Before analy-
sis decays were accumulated by storage at -150◦C to ∼ 300, ∼ 400, ∼ 500 and ∼ 600
decays/cell. Total amount of micronuclei per 100 binuclear cells. Error bars indicate the
standard error of the mean (SEM) of n=3 independent experiments. t-Test irradiated cells
vs. non irradiated negative control (*p-value < 0.05)
4.8.4. γ-Irradiation Induced Micronuclei
SCL-II cells after γ-irradiation at doses of 0.5, 1, 1.5, 2, 4 and 6 Gy contained at each
dose significantly more MN than the negative control harboring on average 1.4 ± 0.6
MN per 100 binuclear cells (Figure 4.24). Across all doses tested, the MN content
constantly increased with 2.6 ± 0.6 MN at 0.5 Gy on average up to a maximum of 18.7
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± 7.7 MN at 6 Gy. The most pronounced increase was observed between 1 to 1.5 Gy
and 2 to 4 Gy.
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Figure 4.24.: Micronuclei in SCL-II cells after γ-irradiation (n=3). Before analysis cells were γ-irradiated
at doses of 0.5, 1, 1.5, 2, 4 and 6 Gy. In parentheses is the number of corresponding
I-125 decays determined with Point-Kernel calculations after Humm et al [58] for SCL-II
cells with a cell nucleus diameter of 10 µm. Total amount of micronuclei per 100 binuclear
cells. Error bars indicate the standard error of the mean (SEM) of n=3 independent
experiments. t-Test irradiated cells vs. non irradiated negative control (*p-value < 0.05)
4.8.5. Comparison of I-125-TFO Induced Micronuclei
To demonstrate the different MN inducing potentials of the analyzed I-125-TFOs and
γ-irradiation, the MN data were directly compared. In order to guarantee compara-
bility between the three I-125-TFOs and the γ-irradiated samples, each data set was
standardized against the negative controls.
By comparing the MN values of the I-125-TFOs at each decays/cell no significant dif-
ference could be detected (Figure 4.25). However, there is a tendency that I-125-
TFO-QRT induces more MN than I-125-TFO-MBS and I-125-TFO-GAPDH at ∼ 300
decays/cell, whereas at ∼ 600 decays/cell I-125-TFO-MBS appears to induce a higher
amount of MN compared to the two other I-125-TFOs.
In comparisson to the γ-irradiated cells only I-125-TFO-QRT induces a significantly
higher number of MN at 300 decays/cell. At all other doses no significant differences
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between the amount of I-125-TFO induced MN and γ-irradiation induced MN could be
detected.
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Figure 4.25.: Micronuclei after γ-irradiation (n=3) or transfection with I-125-TFO-GAPDH (n=3), I-125-
TFO-QRT (n=2) and I-125-TFO-MBS (n=3). Before analysis decays were accumulated
by storage at -150◦C to ∼ 300, ∼ 400, ∼ 500 and ∼ 600 decays/cell. For γ-irradiation the
corresponding decays were calculated with Point-Kernel calculations after Humm et al.
[58] for SCL-II cells with a cell nucleus diameter of 10 µm. Total amount of micronuclei
per 100 binuclear cells. Data standardized against negative controls. Error bars indicate
the standard error of the mean (SEM) of n independent experiments. (*p-value < 0.05)
4.9. Cell Cycle Analysis of SCL-II Cells
The aim was to analyze the cell cycle of SCL-II cells at different time points (0 - 48
h) after transfection with I-125-labeled TFOs, to detect possible cell cycle arrests or
perturbations. SCL-II cells transfected with the corresponding unlabeled TFO were
used as negative controls. Prior to cell cycle analysis the transfected cells were stored
for accumulation of decays at -150◦C. In each experiment and for all investigated TFOs,
experiments were carried out at ∼ 300 accumulated decays/cell. Cells were thawed,
taken into cell culture and analyzed at times indicated, except the 0 h samples where
cells were thawed and immediately analyzed as described in 3.2.17.1.
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4.9.1. Cell Cycle Analysis after I-125-TFO-GAPDH Transfection
SCL-II cells transfected with I-125-TFO-GAPDH showed an almost similar distribution
of cells in the cell cycle phases at 0 h post irradiation1, compared to the negative control
(Figure 4.26). Approximately 40% ± 8% of the cells were in G2/M-, 20% ± 10% in S-
and 40% ± 2% in G1/G0-phase. Within the next 8 h the I-125-TFO-GAPDH transfected
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Figure 4.26.: Fluorescence cytometric analysis of SCL-II cells at different time points after irradiation
with I-125-TFO-GAPDH and accumulated ∼ 300 decays/cell (n=3). As negative controls
served cells transfected with equivalent but unlabeled TFO. Percentage of cells in differ-
ent cell cycle phases G1/G0, S and G2/M (y-axis) is plotted against time after irradiation
(x-axis). (*p-value < 0.05; t-Test irradiated sample vs. negative control)
cells showed a significantly increased percentage of G2/M-phase cells from 40% ± 8%
to 65% ± 8% whereas the negative control cells remained at almost constant percent-
ages of 30% ± 7%. During the following 40 h the ratio of G2/M-phase cells in the I-125-
TFO-GAPDH transfected cells remained significantly increased in comparison to the
negative controls but at the same time they showed a constant decrease to a percent-
age of 37% ± 4% G2/M-phase cells after 48 h. Finally a fraction of ∼ 14% remained
in G2/M-phase when compared to the negative control G2/M fraction. The negative
controls showed no significant changes throughout the period of measurement.
1 Irradiation refers to the time point of cell recultivation after -150◦C storage for accumulation of ∼ 300
decays/cell.
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4.9.2. Cell Cycle Analysis after I-125-TFO-QRT Transfection
SCL-II cells transfected with I-125-TFO-QRT (Figure 4.27) showed a similar distribution
of cells in the cell cycle phases at 0 h post irradiation, compared to the negative control.
Approximately 30% ± 6% of the cells were in G2/M-, 30% ± 4% in S- and ∼ 40% ±
10% in G1/G0-phase. A significant increase of G2/M-phase cells was observed in I-
125-TFO-QRT transfected cells 8 h after irradiation, reaching a maximum of 70% ±
13% at 16 h post irradiation. Within the next 32 h the percentage of G2/M-phase cells
dropped to 40% ± 5% at 48 h but remained significantly increased when compared to
the negative controls. At 48 h a fraction of approximately 17% of the I-125-TFO-QRT
transfected cells still remained in a G2/M-phase arrest. The negative control cells did
not show any significant change within the surveyed 48 h.
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Figure 4.27.: Fluorescence cytometric analysis of SCL-II cells at different time points after irradiation
with I-125-TFO-QRT and accumulated ∼ 300 decays/cell (n=3). As negative controls
served cells transfected with equivalent but unlabeled TFO. Percentage of cells in differ-
ent cell cycle phases G1/G0, S and G2/M (y-axis) is plotted against time after irradiation
(x-axis). (*p-value < 0.05; t-Test irradiated sample vs. negative control)
4.9.3. Cell Cycle Analysis after I-125-TFO-MBS Transfection
SCL-II cells transfected with I-125-TFO-MBS showed that at 0 h 30% ± 5% of the cells
were in G2/M-phase whereas 40% ± 10% were in G1/G0-phase of the cell cycle and
30% ± 5% in S-phase (Figure 4.28). There was no significant difference in cell cycle
distribution when compared to the negative controls at 0 h. At 8 h the percentage of
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G2/M-phase cells increased significantly to 60% ± 5%. Also at 24, 32 and 40 h after
irradiation the percentage of cells in G2/M-phase remained significantly increased in
comparison to the negative controls. That fraction, however, decreased over time until
it nearly reached control level at 48 h.
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Figure 4.28.: Fluorescence cytometric analysis of SCL-II cells at different time points after irradiation
with I-125-TFO-MBS and accumulated ∼ 300 decays/cell (n=3). As negative controls
served cells transfected with equivalent but unlabeled TFO. Percentage of cells in differ-
ent cell cycle phases G1/G0, S and G2/M (y-axis) is plotted against time after irradiation
(x-axis). (*p-value < 0.05; t-Test irradiated sample vs. negative control)
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5.1. In Vitro DNA Triplex Formation and Binding Assay
The sequence of all TFOs investigated, were determined with the TFO target se-
quences search tool provided by http://spi.mdanderson.org/tfo/about.php, except the
two multi-binding site TFOs1. Although all TFOs were designed to the following spe-
cial criteria of a minimum length of 15 bp, a guanine content of minimum 50%, no
pyrimidine interrupts and the purine sequence located on one strand (3.2.6), a triplex
formation could only be verified by EMSA in vitro for 42% of all examined TFOs (Table
4.1). Therefore it can be concluded that a stable triplex DNA formation can not be
predicted by the sequence of TFOs only. This conclusion is supported by TFO sta-
bility experiments performed by Beal and Dervan [9]. Therefore, the confirmation of
DNA triplex formation of every TFO with its specific target sequence by EMSA or a
equivalent method is strongly recommended.
5.2. I-125 Labeling of TFOs
The establishment of the I-125 labeling reaction was one of the most important but
also delicate steps of the present work. The labeling reaction was performed following
the primer extension method described by Panyutin et al. [97]. However, distinct and
very important modifications of the reaction were necessary at some delicate key steps
discussed in the following sections.
The first attempts to separate the labeled TFO from its complementary DNA template
were done by heat denaturation as proposed by Panyutin et al. [97]. To achieve this, a
temperature was chosen which was significantly above the melting temperature (Tm)
of the TFO (∼ 72◦C) but still low enough to avoid the breakup of the biotin-streptavidine
bond (Tm biotin-streptavidine > 81.1◦C [43]) when connecting the biotin template to the
1 TFO-MBS was designed and previously investigated by Sedelnikova et al. [121]. TFO-QRT was not
originally designed as DNA triplex forming but to interfere with DNA quadruplex structures. The in
vitro verification of quadruplex structures is still in progress.
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streptavidine magnetic particles. Extensive experiments revealed that at the chosen
denaturation temperature of 79◦C, which was the best compromise between Tm of
TFO and assumed biotin-streptavidine stability, it was not possible to denature the
TFO from the template with a sufficient yield but induced a breakage of the biotin-
streptavidine bond (Figure 4.3, lanes 1-3). Although Gonzales et al. [43] determined a
Tm for the biotin-streptavidine bond between 81.1◦C and 108◦C our findings are more
in accordance with Holmberg at al. who described that heating of a biotin-streptavidine
bond in aqueous solution to 70◦C is sufficient to efficiently break the bond [54]. As
the biotin-streptavidine bond is stable throughout a wide pH range [54] it turned out
that the denaturation of the TFO from the template by adding NaOH to apply alkaline
conditions is much more suitable. This approach led to the desired denaturation with a
high elution efficiency as can be seen in Figure 4.3, lane 4. However, if the denaturation
at alkaline conditions is continued for more than 10 min the biotin-streptavidine bond
is broken too (Figure 4.3, lane 5). Finally we were able to achieve a labeling efficiency
of ∼ 90% I-125-labeled TFOs in relation to the inserted amount of preTFOs in the
reaction-mix (4.2.2). This corresponded to a total amount of labeled TFOs of ∼ 4.5
pmol and ∼ 0.5 pmol unlabeled TFO in one labeling reaction. In contrast, Panyutin et
al. reached a maximum yield of only 10% labeled TFOs with their strategy [97]. Further
testing with a 20-fold increase of preTFO concentration in the labeling reaction-mix led
to an almost two-fold increased amount of labeled TFO. But at the same time the
actual labeling efficiency was reduced almost 10-fold to ∼ 11% I-125-labeled TFOs.
Moreover, the amount of unlabeled TFOs (preTFO) still included in the reaction mix of
∼ 89 pmol was significantly increased compared to the former labeling reaction strategy
containing only ∼ 0.5 pmol preTFOs. In some DNA triplex formation experiments (data
not given) evidence arose that an increased amount of unlabeled TFOs in a triplex
forming reaction mix is able to inhibit the target binding of the labeled TFOs, possibly
in a sort of competitive inhibition. This finding led to the important conclusion that the
amount of unlabeled TFOs in the reaction mix is an inhibitory factor with regard to TFO
target binding. The concentration of unlabeled TFOs should therefore be kept as low
as possible to allow maximum DNA triplex formation with the respective I-125-labeled
TFO.
The triplex forming ability of TFOs after labeling with I-125 could be confirmed (Figure
4.4, 4.5). The I-125-labeled TFOs investigated bound to their specific target sequence
in the 1695 bp and 212 bp DNA target fragment in vitro. Triplex verification was per-
formed with EMSA (for target fragments < 300 bp) or agarose gel electrophoresis (for
larger targets) combined with autoradiography. To ensure that the band shift in the
EMSA (Figure 4.5 a, ) is predominantly due to binding of I-125-labeled TFOs the
80
5. Discussion
EMSA gels were additionally analyzed via autoradiography (Figure 4.5 b). A band shift
in the EMSA and a corresponding signal in the autoradiography ensured the triplex
forming abilities of the I-125-labeled TFOs. The autoradiographic analysis was also
used by Panyutin et al. [96] to verify triplex formation of I-125-labeled TFOs. To ad-
ditionally confirm the binding specificity of the TFO, they varied the binding conditions
(pH value) until no triplex formation could be detected anymore. In the present work the
binding specificity was underlined by the use of a non-complementary TFO, which, as
expected, failed to form a DNA triplex structure (Figures 4.4 b, lane 2). A non-specific
binding of TFOs to the target fragments can therefore be neglected in vitro.
5.3. DNA Double-Strand Break Analysis in vitro
One of the main aims of the present work was to show that an I-125-labeled TFO is
able to induce a DSB at a defined specific sequence in a DNA target fragment. The
results of the DSB analysis (4.3) showed that after an accumulation time of 143 days
approximately 40% of the target strand broke into two defined breakage fragments of
the expected size (Figure 4.7, ). These findings are in good agreement with the
results of Sedelnikova et al. [117], who described 50% TFO-induced DSB in plasmid
DNA after 136 days of decay accumulation, using 6-aminopyrazolo[3,4-d ]pyrimidine-
4(3H)-one-(8-aza-7-deazaguanine) (PPG) modified TFOs. This modification enhances
the triplex formation [10], and leads to 100% target binding of the TFOs at equimolar
ranges of TFO and plasmid DNA [117]. That might explain the higher DSB percentage
in comparison with the present work.
It could be shown that after exposure of the DNA target to non-specific I-125-labeled
TFOs no distinct breakage fragments were detectable (Figure 4.7, lane 2). This finding
underlines the results of Panyutin et al. [101] who found also that the effect of unbound
I-125-TFOs is only of minor nature.
Beside the percentage of induced DSBs (∼ 40%), we additionally determined the
DSB/decay rate and found that approximately 0.6 DSBs were induced per decay of
bound I-125-TFO. This result is slightly different from the results of Panyutin et al. [101],
who found 0.46 DSB/decay. The higher DSB/decay value obtained in the present work
might be induced as a non-directed side effect by unbound I-125-TFOs in the reaction.
In addition, Panyutin et al. [101] found an induction of 0.17 DSB/decay for free I-125-
TFOs. Consequently, 0.46 DSB/decay for bound TFOs and 0.17 DSB/decay for free
TFO, equals a total of 0.63 DSB/decay, which is close to the DSB/decay rate of 0.6
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DSB/decay determined in the present work. Moreover, a DSB ratio of 0.6 DSB/decay
fits in the coherence of I-125 target distance and DSB induction, investigated by several
other groups [114, 81, 7, 64]. These groups determined approximately 1 DSB/decay
for I-125 directly incorporated in the DNA and with increasing distance to the binding
site a decrease to 0.10 DSB/decay for unbound I-125.
On the agarose gel of the DSB analysis (Figure 4.7 a, lanes 1 and 2) one more band
at 500 bp appears, representing a possible hint for non-specifically induced breaks.
However, our explanation is, that this is an unspecific amplificate from the PCR of the
target fragment [110]. It can be excluded that this fragment originates from the target
as there was no corresponding signal detected in the southern blot (Figure 4.7 b) using
probes specific for the target and the breakage fragments, respectively.
5.4. Biokinetic of TFOs in SCL-II Cells
In the present work it was a major goal to investigate the biokinetics of TFOs in the
cellular environment. It should be elucidated how efficient TFOs can be transferred
into cells, where TFOs are localized and to determine the persistence of TFOs in the
cellular environment.
The biokinetic studies confirmed that the applied transfection protocol caused an ini-
tial efficient transfer of TFOs into the cytoplasm and cell nucleus (Figure 4.9). The
substantial loss of more than ∼ 50% TFO positive nuclei detected in the first 6 h after
transfection matches the results of Forsha et al. [36] who found after an initial accu-
mulation of fluorescence-labeled oligonucleotides, which are analogues of TFOs, in
the nucleus, a pronounced loss of fluorescence signal. That loss was caused by a
translocation of oligonucleotides from the nucleus into the cytoplasm. Additionally to
a possible translocation process the loss of TFO positive nuclei could also be due to
a degradation of TFOs. Degradation processes cannot be generally excluded but are
unlikely since Sedelnikova et al. [118] confirmed triplex stability in HeLa cells for at
least 48 h. This could be also demonstrated during earlier studies using FRET analy-
sis technique (Kriehuber, personal communication). Since cells were proliferating, the
observed significant decrease of TFO positive cells and the smooth decline of TFO
positive nuclei 48 h and 72 h post-transfection is probably due to further dilution of the
fluorescence signal, caused by cell division. However, TFO signals were detectable
throughout the experiment (0 - 72 h). Moreover, it has to be kept in mind that a cell
is defined as TFO negative, if the fluorescence signal drops below the set threshold.
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However, it is very likely that there is a certain amount of TFO molecules left in the
cells, due to the detection limit in flow cytometry. This limit depends on reagents, stain-
ing, and instrument parameters and for the most common procedures and reagents
the sensitivity limit is ∼ 2000 molecules [148]. It is therefore more than likely that there
is a reasonable quantity of TFOs left in cells that are methodology defined as TFO
negative.
The results of the live cell imaging confirmed the dynamic characteristic of TFO lo-
cation in the cells. Cells harboring TFOs in the nucleus showed a high variation in
signal intensity during the 22 h observation time (Figure 4.11). However, the overall
amount of TFO-positive nuclei remained constant at ∼ 21%, reflecting the flow cyto-
metric results very well. The variation might be explained as all pictures were taken at
the same focal plane and it is most likely that the TFOs were out of focus due to diffu-
sion or transport processes. The average retention period of TFOs in the nuclei was
4 h, which is in good accordance with the microscopic analysis of Forsha et al. [36]
who observed a translocation of oligonucleotides from the nucleus into the cytoplasm
within approximately 5 h. However, it has to be recalled that microscopical analysis
of fluorescence-labeled TFO is somehow difficult to interpret, since it is likely that the
observed signals represent only large aggregations of TFOs. Single TFOs can not be
observed by conventional microscopic techniques.
5.5. Induction of DNA Double-Strand Breaks
The 53BP1 assay was used to quantify the DNA DSBs, induced in SCL-II cells af-
ter transfection with different I-125-labeled TFOs with increasing decays/cell (4.5) and
each 53BP1 focus was regarded as one DSB [115]. The single-binding-site I-125-
TFO-GAPDH and the multi-binding-site I-125-TFO-MBS induced 3 foci/cell at similar
accumulated decays of ∼ 480 decays/cell and ∼ 450 decays/cell, respectively. That ob-
servation is quite remarkable as a multiple-binding-site I-125-TFO with ∼ 7000 targets
in the genome is expected to induce more foci/cell. However this holds true only under
the assumption that all possible target sequences are bound by the TFO. The employed
transfection method delivered on average approximately 6x103 ± 20% I-125-TFO per
cell (free and DNA bound I-125-TFO) at a transfection efficiency of ∼ 85%. According
to that a 100% saturation of all 7000 putative targets with I-125-TFO is not possible.
Due to this it can be concluded, that the multi-binding-site I-125-TFO-MBS is not able
to unfold its maximum DSB inducing potential. This assumption is in good accordance
with results of Sedelnikova et al. [121] and Panyutin et al. [102], who achieved higher
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I-125-TFO concentrations of ∼ 1x107 I-125-TFOs per cell and observed a 1.9-fold in-
creased induction of foci for a multi-binding-site I-125-TFO with ∼ 7000 targets com-
pared to a single-binding-site I-125-TFO. It can be therefore concluded that a higher
concentration of I-125-in the cell would probably lead to a stronger DSB induction of
multi-binding-site I-125-TFO compared to single-binding-site I-125-TFOs. That expla-
nation does also account for the relatively low foci induction of the multi-binding-site
I-125-TFO-QRT. Although possessing > 40-times more putative targets than the other
two I-125-TFO, only a 1.5-fold stronger foci induction could be observed.
A further question that might arise from the given data is, how can a single-binding-site
TFO like I-125-TFO-GAPDH induce more than two foci/cell? For this TFO a maximum
of 3.5 foci/cell was measured, which is likely to be a result of the measured background
foci of 0.8 foci/cell plus an near-tetraploid fraction (∼ 20 - 40%) of the SCL-II cell line
[132] almost doubling the putative target number and therefore enabling a DSB content
of more than 2.
The detected slight increase of foci/cell over storage time in the negative controls is
in good accordance with the results of Fairbairn et al. who found an increase of DNA
damage due to freezing of cells but only a minor further increase after longer time
storage [30]. It can therefore be neglected that the increase of foci found in the I-125-
TFO transfected cells is only due to the varying storage periods.
The analysis of the uniformity of TFO uptake by quantification of cells with no visible
foci and cells with multiple foci revealed in the negative controls a fraction of 87%
containing on maximum 2 foci/cell (∼ 0.8 foci/cell). That background DSB level is
in good accordance with an average of ∼ 0.9 foci/cell and a maximum of 3 foci/cell
detected by Sedelnikova et al. in non-radioactive TFO transfected negative controls
[121]. For all three I-125-TFOs a cell fraction of ∼ 62% ± 5% did not contain more than
2 foci/cell, whereas ∼ 38% ± 5% of cells possessed at least 3 foci/cell or more. These
percentages are in good correspondence to the observed transfection efficiency with
approximately 34% ± 25% of cells containing TFOs in the nucleus. In conclusion, cells
where the I-125-TFOs are located in the nucleus seem to represent the fraction of cells
with the highest DNA damage.
Looking at the multi-binding-site I-125-TFO-MBS and single-binding-site I-125-TFO-
GAPDH both inducing in ∼ 55% of cells not more than 8 foci/cell and in ∼ 40% no
foci, the different target numbers were not clearly reflected. In this context the group of
Panyutin at al. [102] reported a distribution of foci that was in good correspondence to
the different target numbers of their investigated I-125-TFOs. Panyutin et al. showed for
the multi-binding-site I-125-TFO a substantial percentage of cells containing between
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20 and 30 foci/cell, whereas the single-binding-site I-125-TFO induced between 5 and
10 foci/cell only. This disagreement with the results of the present study might also be
explained by the higher intracellular I-125-TFO concentration achieved by Panyutin et
al.
However, 12% of I-125-TFO-QRT transfected cells contained on average between 9
and 14 foci/cell, which is twice more than that induced by the other two I-125-TFOs.
This might be explained by the very high target number of > 300,000 putative targets
per cell for I-125-TFO-QRT. The high target number allows numerous TFO-formation
even at low intracellular concentrations of I-125-TFO-QRT.
5.6. Cell Killing
To study the cytotoxic effects of I-125-TFO-QRT, I-125-TFO-MBS and I-125-TFO-GAPDH
on transfected SCL-II cells, cell survival experiments were carried out with different ac-
cumulated decays (Figure 4.14). Additionally, experiments after (I-125)IdU incorpora-
tion (Figure 4.15) and γ-irradiation (Figure 4.16) were performed, to allow the compar-
ison between radiation qualities and different DNA localization of I-125.
The γ-irradiated cells showed, as described in the literature [12], the typical survival
curve, with an initial slope in the low dose range, typical for sparsely ionizing radia-
tion (low-LET) (Figure 4.16). In contrast to the γ-irradiated cells, the incorporation of
(I-125)IdU into DNA led to the characteristic straight exponential survival curve de-
scribed for densely ionizing radiation (high-LET) (Figure 4.15). Even at low numbers
of accumulated decays and hence at low radiation doses the DNA incorporated I-125
caused pronounced cytotoxicity. Comparing the D37 value of the γ-irradiated cells of
3.5 Gy with the D37 value of the cells after (I-125)IdU incorporation of ∼ 0.83 Gy 2, re-
vealed a > 4-fold stronger reduction of colony forming ability for the DNA incorporated
Auger electron emitter I-125. This finding is in good agreement with the high relative
biological effectiveness (RBE) for I-125 of up to ∼ 7 described in the literature [88]. In
contrast when located extracellular or cytoplasmic, I-125 has an RBE of ∼ 1.3 - 1.4 as
could be demonstrated by Ling et al. and Kassis et al. [76, 65] and induces survival
curves more resembling to low-LET irradiation [65, 113].
The observed results of the CFA (Figure 4.14) corresponded very well to the results
of the 53BP1 assay (Figure 4.12). I-125-TFO-QRT induced the highest DSB number
2 Point-Kernel dose calculation after Humm et al. [58] for SCL-II cells with a cell nucleus diameter of
10 µm.
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and showed concordantly the strongest cytotoxicity of all three tested TFOs. I-125-
TFO-QRT displays an almost twice as high cytotoxicity and a ∼ 1.5-fold increased
53BP1 foci number/cell per decay when compared to I-125-TFO-GAPDH and I-125-
TFO-MBS. This result is not unexpected as I-125-TFO-QRT possesses the highest
target number in the genome of all three tested TFOs, with more than ∼ 300,000 puta-
tive target sequences overall, and ∼ 14,700 located in promotor and regulatory regions
[133, 59]. In view of theses results one could conclude that the general cytotoxic ef-
fect of I-125-TFOs depends largely on the target quantity, hence number of putative
targets and less on the localization or function of the targeted sequence. Interestingly,
however, the single-binding-site I-125-TFO-GAPDH, binding in the promotor region of
the GAPDH gene only, showed an almost as high cytotoxicity as the multi-binding-
site I-125-TFO-MBS, the latter having ∼ 7000 potential targets in the whole genome
[121]. This could easily reflect the biological importance of the selected target gene
and strongly suggests, that targeting one single essential target in the genome can be
at least as cytotoxic as targeting multiple, but non-essential targets.
This hypothesis is supported by the work of Sedelnikova et al [121], who compared
the cytotoxicity of the same I-125-TFO that was used in the present work, i.e. I-125-
TFO-MBS (yet labeled with three I-125 molecules) to a single-binding-site I-125-TFO
binding in the HPRT gene. This gene is part of the purine recycling pathway in human
cells and was previously shown to be a non-essential gene for cells growing in culture
[128]. By comparing the non-essential single-binding-site I-125-TFO-HPRT to a multi-
binding-site TFO, Sedelnikova et al. [121] observed a 1.7 times higher cytotoxicity of
the multi-binding-site I-125-TFO-MBS. In contrast, the observed strong cytotoxicity of
the single target binding I-125-TFO-GAPDH in the present work might be explained by
the crucial importance of GAPDH in glycolysis, which is essential for growing cells in
culture [3].
Therefore, the question arises whether it is the target quantity or the target quality that
determines the observed cytotoxicity. The obtained results allow conclusions in both
directions. It was shown that a single-binding-site TFO (I-125-TFO-GAPDH) can be
as cytotoxic as an multi-binding-site TFO (I-125-TFO-MBS), which is probably due to
the target quality. However, the I-125-TFO-QRT, which possesses the highest target
number, induced the most pronounced cytotoxic effect per decay, which in turn might
indicate that the target quantity is of major importance. Considering that I-125-TFO-
QRT induced almost twice as much 53BP1 foci per decay when compared to I-125-
TFO-MBS and I-125-TFO-GAPDH it is highly probable that the amount of targets and
hence induced DSB per decay is much more relevant for cell killing than the quality of
the target.
86
5. Discussion
It should also be mentioned that I-125-TFO-QRT was not originally designed to form
DNA triplices but as an oligonucleotide with a high probability of forming secondary
structures caused by the guanine motif contained in it [95]. It is well known that nu-
merous genes possess guanine-rich sequences in promotor regions as well as in other
regulatory and non-regulatory structures of the genomic DNA, which enables them to
form various secondary structures, including guanine quadruplices [95]. We conclude
therefore that the I-125-TFO-QRT binds within these regions as part of a quadruplex
structure. The observed strong cytotoxicity can be explained by multiple binding and
disruption of these sequences, leading to the enhanced cytotoxic effect of I-125-TFO-
QRT. Finally we cannot determine with certainty that the observed cytotoxic effects are
rather due to the quantity of TFO targets or if the proper localization of the TFOs is of
major importance. As already mentioned, the induced effects are remarkable, consid-
ering the relatively low achieved concentrations of I-125-TFOs in the cells, but probably
not pronounced enough to reflect more clearly the distinct TFO qualities. However, we
assume more distinct effects at higher cellular I-125-TFO concentrations.
A question which might also arise from the present data is to what extent the measured
cytotoxic and genotoxic effects are due to I-125-TFOs, which are not bound to their
DNA targets. It is known that I-125 has to be in close proximity to the DNA to induce
its pronounced cytotoxicity due to the numerous ejected low energy auger electrons.
Nevertheless, I-125 emits also higher energy electrons with longer range as well as
γ-irradiation [62], which might also damage cellular components and reduce colony
forming ability. This has been investigated by Sedelnikova et al. [120] who found a
measurable cytotoxic effect for unbound I-125-ODNs in the cell. However, the observed
cytotoxicity was more than 3 orders of magnitude below the cytotoxic effect measured
for incorporated (I-125)IdU and reached the D37 value at 1.3x104 decays/cell. Since
this value is nearly 40-fold higher when compared to the D37 values determined for
I-125-TFOs investigated in the present work, we assume that the effect of unbound
I-125-TFO can be neglected in that context.
When comparing the survival data of I-125-TFO transfected cells to the transfection
efficiency, it seems curious that over ∼ 90% of cells can be killed at a transfection effi-
ciency of ∼ 85% and about ∼ 30% of TFOs in the nucleus. As already mentioned in 5.4,
however, the flow cytometry used for determination of the transfection efficiency has an
approximate sensitivity limit of ∼ 2000 molecules [148]. Therefore we assume that the
amount of TFO that cannot be detected in the flow cytometry due to a concentration
below the detection limit is still high enough to induce a pronounced cytotoxic effect,
when I-125-labeled TFO are used.
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5.7. Relative Gene Expression Analysis
According to the existing literature, the approach of using a gene specific binding I-
125-labeled TFO to manipulate a gene on the expression level, has not been applied
before. Up to now I-125-labeled TFOs were investigated only with regard to TFO deliv-
ery and induction of gene specific DSBs [119, 116, 99] but without analyzing specific
alterations of gene expression. In the present work three different I-125-TFOs binding
within the genes GAPDH, BRCA1 and BCL2 were investigated. Additionally, the effect
of the multi-binding-site I-125-TFO-QRT on all three genes was investigated. Before
analysis transfected cells were stored at -150◦C for accumulation of ∼ 300 decays/cell.
300 accumulated decays were chosen as it largely represents the average D37 value
determined in the precedent CFAs (Figure 4.14).
The GAPDH gene was chosen as a TFO target due to its constant high expression
level in the cell, and therefore allows good quantification of potential TFO-induced gene
expression alteration. Targeting the GAPDH gene with the specific binding I-125-TFO-
GAPDH resulted in a significant down-regulation of the GAPDH gene expression (Fig-
ure 4.18). We suggest that this reflects the DNA damage caused by GAPDH bound I-
125-TFO-GAPDH and the subsequent decay of I-125. This interpretation is supported
by the observed induction of site-specific DSBs in our in vitro studies (Figure 4.7), and
the general geno- and cytotoxicity of I-125-TFO-GAPDH in the 53BP1 foci assay and
the CFA (Figure 4.12 and 4.14). It also correlates very well with the findings of Sedel-
nikova et al. [119], who were able to show the induction of specific DSBs in the human
MDR1 gene in KB-V1 cells by a specific binding I-125-labeled TFO. Furthermore the
results in the present work emphasize the high target specificity of I-125-TFO-GAPDH
when compared to I-125-TFO-QRT, which possesses a much higher cytotoxicity (4.14),
but barely affects the gene expression of GAPDH.
The target sequence of I-125-TFO-GAPDH is located in the promoter region 422 bp
upstream of the GAPDH gene. From that it might be concluded that the decrease in
gene expression is not due to the decay of I-125 and the subsequently caused DNA
damage, but to a blockage of the promoter region by the TFO itself. The group of
Cooney et al. [20] used an unlabeled TFO binding 115 bp upstream of the c-myc gene
transcription origin, to successfully downregulate the gene expression. In the present
work this effect can be ruled out as the negative controls contained TFO-GAPDH with-
out the I-125 labeling, and no gene expression alterations could be detected in these
samples.
88
5. Discussion
BRCA1 is part of the cellular DNA damage response and plays an important role in cell
cycle checkpoint activation and DNA damage repair [141]. A loss of function mutation
of BRCA1 increases the risk for breast or ovarian cancer [79].
A significant gene expression alteration of BRCA1 in I-125-TFO-BCL2 transfected cells
could not be detected (Figure 4.19). A possible explanation for the lack of any gene
expression alteration might be the position of the primer pair that was used for the qRT-
PCR. The amplified region for the qRT-PCR is located upstream of the TFO binding site.
Hence it is possible that even though the I-125-TFO induced damage at its binding site,
the region upstream of the TFO binding site was still transcribed and led therefore to
an unaltered signal in the qRT-PCR. The primers, however, were positioned under the
assumption that a damage induced anywhere within the gene sequence would cause
a general stop of transcription as could be shown by Donahue at al. [28].
In contrast to I-125-TFO-BCL2 the multi-binding-site I-125-TFO-QRT induced a pro-
nounced down-regulation of the BRCA1 gene expression. It is likely that I-125-TFO-
QRT caused widely spread damage to the genome, which might cause the observed
down-regulation. That hypothesis is supported by the results of several groups who
could show a significant downregulation of the BRCA1 mRNA level in human cancer
cell lines after treatment with different DNA damaging agents such as UV irradiation
[4, 31, 145].
The proto-oncogene BCL2 was originally discovered as part of a t(14;18) chromoso-
mal translocation leading to BCL2 overexpression, frequently found in non-Hodgkin´s
lymphomas [134]. Overexpression of BCL2 also occurs in many other types of human
tumors, including cancers of prostate, colon, and lung [107]. Therefore, BCL2 repre-
sented a possible candidate gene for I-125-TFO based antigene radiotherapy [99].
Interestingly, in I-125-TFO-BCL2 transfected SCL-II cells a 2-fold upregulation of the
BCL2 gene expression was detected when compared to the negative control. In con-
trast to that, we initially expected a downregulation of the gene expression due to the
complex DNA damage in the gene that is assumed to be caused by the BCL2 bound I-
125-TFO-BCL2. According to existing literature there has been no evidence so far that
DNA damage induces an upregulation of BCL2 gene expression, whereas a downreg-
ulation of BCL2 after DNA damage could be shown in several studies [17, 35, 77]. A
possible explanation for this observation might be drawn from the results of Varga et
al. who showed that a DSB inserted at a predetermined location was able to induce
complex DNA rearrangements such as inversions, deletions and translocations [135].
Therefore, it might be hypothesized that the site-specific I-125-TFO-BCL2 induced DSB
led to a translocation of fragments or of the whole BCL2 gene under the influence of a
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stronger promotor, inducing the increased gene expression. This is supported by the
location of the binding sequence of the used I-125-TFO-BCL2, which is in close vicinity
of the known major breakpoint region (MBR) in the BCL2 gene [19]. Breaks in this
region lead to an increased translocation frequency of the BCL2 gene under the influ-
ence of the IgH enhancer located on chromosome 14, resulting in an overexpression
of BCL2 [146]. Naturally, one has to bear in mind that the induced translocations are
rare events happening only in a fraction of cells. As, however, the BCL2 mRNA level in
cells without the t(14;18) translocation is generally very low [122], it should be possible
to detect also small increases in the mRNA level.
In contrast, the non-specific I-125-TFO-QRT led to a significant 4-fold downregulation
of BCL2 gene expression in transfected SCL-II cells. This multi-binding-site I-125-TFO
is supposed to cause widely spread damage to the genome, which might lead to the
observed downregulation. That would be in good agreement with findings of Chen et
al. who detected a ∼ 5-fold downregulation of BCL2 gene expression after induction of
DNA damage in human leukemia cells after exposure to 10 Gy of X-rays [17].
5.8. Induction of Micronuclei
All three tested I-125-TFOs induced, between ∼ 300 and ∼ 400 decays/cell, a signifi-
cantly increased number of MN when compared to the negative controls (Figure 4.21,
4.22 and 4.23). Only I-125-TFO-MBS and I-125-TFO-QRT, both binding to multiple
targets, induced also at higher decays/cell significantly increased MN numbers. The
lack of a clear positive MN-dose-dependency in all three analyzed I-125-TFOs that has
been shown after γ-irradiation (Figure 4.24) is striking. A possible explanation might
be the rather short cytochalasin B incubation time of the cells after decay accumula-
tion, in combination with a radiation induced G2/M cell cycle arrest, that was confirmed
thereupon (Figure 4.26, 4.27 and 4.28). In consequence not all cells underwent cell
division and since MN formation requests mitosis, cells have to undergo cell division at
least once to form MN [34]. Ludwikow et al. detected a decrease in MN formation in
CHO cells at higher doses of DNA incorporated (I-125)IdU, also assuming a connection
between cell cycle perturbences and MN amount. They concluded that an increased
cytochalasin B incubation before MN analysis should overcome the problem. However,
an increase of the incubation period did not lead to a significant change in MN content
[83]. In the present work an elongated cytochalasin B incubation up to 48 h did not
make any difference in MN content either (data not shown). It is therefore more likely
that the observed MN-dose-response is a consequence of the increasing cell killing at
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higher doses (Figure 4.14) in combination with a constant fraction of non-transfected
cells (∼ 15%; transfection efficiency ∼ 85%) receiving no dose. Since the MN assay
displays only living cells, the non-transfected cell fraction becomes more dominant the
more the transfected cells are reduced by cell killing with increasing dose. This is
supposed to create the appearance of a decreasing MN number with increasing dose.
This assumption is additionally supported by the fact that the strongest MN decrease
was induced by I-125-TFO-QRT, showing also the strongest cell killing effect of the
analyzed I-125-TFOs.
The comparison of the I-125-TFOs with each other did not reveal significant differ-
ences of their MN inducing potential. Hence, the results of the 53BP1 assay, with
I-125-TFO-QRT inducing ∼1.5-fold more 53BP1 foci, were not significantly reflected
in the MN frequencies. However, there is experimental evidence that at ∼ 300 and ∼
400 decays/cell a higher number of MN are observed for the two multi-binding I-125-
TFO-QRT and I-125-TFO-MBS when compared to the single-binding-site I-125-TFO-
GAPDH. Additionally I-125-TFO-QRT induced at ∼ 300 decays/cell significantly more
MN than γ-irradiation. Therefore it is likely that the DSB inducing potential of a I-125-
TFO is also reflected in chromosomal damage. This assumption is supported by the
general acceptance that unrepaired or misrepaired DNA DSBs lead to the formation of
chromosome aberrations [60].
5.9. Cell Cycle Analysis of SCL-II Cells
It is well known that exposure to ionizing radiation induces cell cycle delays in a variety
of cells [87]. Such delays may appear in G1-phase, G2/M-phase or in S-phase of the
cell cycle. Cell cycle arrests are highly conserved from yeast to mammalian cells and
DNA damage as e.g. caused by ionizing radiation are potent causes for cell cycle ar-
rests [87]. In the present work SCL-II cells either transfected with I-125-TFO-GAPDH,
I-125-TFO-QRT or I-125-TFO-MBS displayed a pronounced cell cycle arrest in G2/M-
phase with approximately 60% of cells arrested in G2/M, 8 h post irradiation3. These
observations are in good agreement with results obtained by Xu et al. showing a tran-
sient G2/M arrest in several tumor cell lines after irradiation with 6 Gy of γ-rays [142].
By 16 h post irradiation cells of I-125-TFO-GAPDH and I-125-TFO-MBS transfected
samples began to reenter cell cycle whereas the I-125-TFO-QRT transfected cells dis-
played a further increasing fraction of G2/M arrested cells. The more pronounced G2/M
3 Irradiation refers to the time point of cell recultivation after -150◦C storage for accumulation of ∼ 300
decays/cell.
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arrest induced by I-125-TFO-QRT might be due to the number of potential target se-
quences of I-125-TFO-QRT in the genome and hence the resulting numerous DNA
damages. Thus, it might be concluded that the more DNA damage is induced, the
more pronounced is the G2/M arrest. That assumption is supported by the general
assumed dose and damage dependency of the cell cycle delay detected in various cell
lines [143, 142].
With regard to the radiation quality the question arises whether Auger electron emitter
are able to induce more pronounced cells cycle delay than γ-irradiation or α-particles.
Lücke-Huhle et al. could show a G2/M arrest of 45% at 8 h after ∼ 0.35 Gy of α-particles
irradiation and ∼ 2 Gy of γ-irradiation, equaling an RBE of 5.7 [84]. Compared to the
average G2/M arrested fraction in the present work of 60% after 8 h post irradiation with
∼ 300 decays/cell, which equals a cell nucleus dose of ∼ 1 Gy4, this would equal a RBE
of ∼ 2.6 compared to γ-irradiation. It is obvious that this is only a rough estimation but
nevertheless these RBEs would match very well the RBEs of the I-125-TFOs observed
in the performed cell survival experiments displaying an RBE of 1.7 - 3 at a radiation
dose to the cell nucleus of 1 Gy.
4 Point-Kernel dose calculation after Humm et al. [58] for SCL-II cells with a cell nucleus diameter of
10 µm.
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The present work demonstrated that DNA triplex-forming oilgonucleotides (TFO) do
bind to their specific targets in a sequence-specific manner. It could be shown that
software-based design of TFOs as well as any chemical modification of TFOs e.g.
such as adding I-125-labeled nucleotides or fluorochromes demands the experimental
verification of the successful DNA triplex formation in vitro.
I-125-labeled TFOs are able to induce site-specific DSBs in DNA fragments in vitro. It
could be further demonstrated that fluorochrome-labeled TFOs persist in a cellular en-
vironment for more than 72 h and that I-125-labeled TFOs cause putative site-specific
DNA damage, leading to a decrease in cell survival and a corresponding increase of
53BP1 foci in the human SCL-II cell line. In that context the comparison of single-
binding-site TFOs with multiple binding TFOs gave experimental evidence that the cy-
totoxicity of an AEE-labeled TFO seems to depend on target quantity as well as on
target quality.
In addition, there is good evidence that I-125-labeled TFOs may not only target DNA
by the formation of a DNA triplex structure but possess, with adopted base sequence,
the potential to bind to guanine rich sequences as a part of a quadruplex structure.
This significantly increases the potential of AEE-labeled TFOs to be used to introduce
complex DNA lesions in cells and cell lines.
It could also be demonstrated that I-125-labeled TFOs targeting single genes can alter
gene expression of the specifically targeted gene. Both, a specific down- as well as an
upregulation of gene expression could be shown. It is likely that the influence on gene
expression is due to the site-specific induction of DSBs.
The TFO based carrier system might be a very useful tool for future targeted cancer
therapy approaches and, more recently, for basic DNA repair research.
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The future strategies are divided in short term tasks, which mostly comprise further
improvement of the established methods or additional techniques for verification of the
achieved results, and middle to long term tasks, which rather refer to potential fields
the TFO based system could be used upon.
Short Term Tasks:
- Although we could determine the stability of TFOs in a cellular environment, there
is evidence that TFOs are degraded to a certain extent. To increase TFO stability
modifications of the employed oligonucleotides e.g with a phosphorothioate or phos-
phoramidate backbone should be examined to enhance cellular persistence.
- The labeling of TFOs with I-125 was well established and reached an efficiency of
∼ 90% but nevertheless we found indications that the remaining fraction of unlabeled
TFOs can induce inhibitory effects on the DNA triplex formation with labeled TFOs.
Therefore, the labeling reaction has to be optimized in a way to separate the labeled
TFOs from unlabeled residues.
- One very important task for future research is to elucidate the amount of non-directed
effects of I-125-labeled TFOs in the cell. Non-bound I-125-labeled TFOs might induce
a certain degree of cytotoxicity and non-specific DNA damage, respectively, when lo-
cated in the nucleus, as was shown by Sedlenikova et al. [120]. To quantify this effect
I-125-TFOs with no obvious target in the genome, or the use of TFOs with a comple-
mentary oligonucleotide preventing DNA binding, shall be examined.
- Based on the results of the 53BP1 assay it seems that the obvious I-125-TFO induced
effects become more distinct, when higher intracellular concentrations of I-125-TFOs
are achieved. Thus one further task is to increase the efficiency of TFO delivery into
the cells either by improving the technique used in the present study or by establishing
a liposome-based method.
- Investigation of the I-125-TFO damaging potential on the chromatin level, without the
limitations of the MN assay e.g. by using In-Situ Hybridisation techniques.
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Middle to Long Term Tasks:
- Auger electron emitter labeled TFOs allow the site-specific induction of complex DNA
lesions and are therefore an interesting tool for DNA-repair-research. Numerous struc-
tures such as promotors, exons and introns but also hetero- or euchromatic regions
can be targeted in a sequence-specific manner. The repair mechanisms and repair
efficiencies of such DNA structures in a cellular environment are at present barely un-
derstood. Therefore, addressing these topics using AEE-labeled TFOs will certainly be
part of future studies.
- Interesting applications of AEE-labeled TFOs might also be in the field of molecular
microbiology with focus on anti-infectives research. Bacteria resistant against most
available antibiotics constitute a severe problem in clinical surgery and therapy [80].
In many cases single base mutations in the bacterial genome are sufficient to extend
the resistance spectrum and to render the available antibiotics almost noneffective. An
AEE-labeled TFO, specific for a sequence in the resistance gene of a bacterium might
induce a downregulation and a reduced production of resistance factors. Combined
with a regular antibiotic therapy this approach might increase therapeutic success in
severe multi resistant bacterial inflammations.
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